{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:30:37Z","timestamp":1794349837524,"version":"4.9.0"},"reference-count":626,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor T (CAR-T) cell therapies have transformed the treatment of relapsed\/refractory (R\/R) B-cell malignancies and multiple myeloma by redirecting activated T cells to CD19- or BCMA-expressing tumor cells. However, this approach has yet to be approved for acute myeloid leukemia (AML), the most common acute leukemia in adults and the elderly. Simultaneously, CAR-T cell therapies continue to face significant challenges in the treatment of solid tumors. The primary challenge in developing CAR-T cell therapies for AML is the absence of an ideal target antigen that is both effective and safe, as AML cells share most surface antigens with healthy hematopoietic stem and progenitor cells (HSPCs). Simultaneously targeting antigen expression on both AML cells and HSPCs may result in life-threatening on-target\/off-tumor toxicities such as prolonged myeloablation. In addition, the immunosuppressive nature of the AML tumor microenvironment has a detrimental effect on the immune response. This review begins with a comprehensive overview of CAR-T cell therapy for cancer, covering the structure of CAR-T cells and the history of their clinical application. It then explores the current landscape of CAR-T cell therapy in both hematologic malignancies and solid tumors. Finally, the review delves into the specific challenges of applying CAR-T cell therapy to AML, highlights ongoing global clinical trials, and outlines potential future directions for developing effective CAR-T cell-based treatments for relapsed\/refractory AML.<\/jats:p>","DOI":"10.1038\/s41392-025-02269-w","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T19:02:28Z","timestamp":1751569348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":344,"title":["CAR-T cell therapy for cancer: current challenges and future directions"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7666-5055","authenticated-orcid":false,"given":"In\u00e9s","family":"Zugasti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lady","family":"Espinosa-Aroca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudyna","family":"Fidyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Mulens-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Diaz-Beya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3064-1648","authenticated-orcid":false,"given":"Manel","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Urbano-Ispizua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2183-7443","authenticated-orcid":false,"given":"Talia","family":"Velasco-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"2269_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo, C. D., Erba, H. P., Freeman, S. D. & Wei, A. H. Acute myeloid leukaemia. Lancet 401, 2073\u20132086 (2023).","journal-title":"Lancet"},{"key":"2269_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian, H. et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 11, 41 (2021).","journal-title":"Blood Cancer J."},{"key":"2269_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265\u20131281.e24 (2019).","journal-title":"Cell"},{"key":"2269_CR4","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng, A. G. X. et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat. Med. 28, 1212\u20131223 (2022).","journal-title":"Nat. Med."},{"key":"2269_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3324\/haematol.2022.280801","volume":"108","author":"S Kayser","year":"2023","unstructured":"Kayser, S. & Levis, M. J. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica 108, 308\u2013320 (2023).","journal-title":"Haematologica"},{"key":"2269_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz, K. W. et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am. J. Hematol. 99, 615\u2013624 (2024).","journal-title":"Am. J. Hematol."},{"key":"2269_CR8","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.21.02823","volume":"40","author":"TM Kadia","year":"2022","unstructured":"Kadia, T. M. et al. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 40, 3848\u20133857 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR9","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei, A. H. et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135, 2137\u20132145 (2020).","journal-title":"Blood"},{"key":"2269_CR10","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl, A. E. et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N. Engl. J. Med. 381, 1728\u20131740 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR11","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1182\/blood.2021011583","volume":"139","author":"AE Perl","year":"2022","unstructured":"Perl, A. E. et al. Follow-up of patients with R\/R FLT3- mutation\u2013positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 139, 3366\u20133375 (2022).","journal-title":"Blood"},{"key":"2269_CR12","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos, P. et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N. Engl. J. Med. 386, 1519\u20131531 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR13","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1182\/bloodadvances.2017009829","volume":"1","author":"AE Perl","year":"2017","unstructured":"Perl, A. E. The role of targeted therapy in the management of patients with AML. Blood Adv. 1, 2281\u20132294 (2017).","journal-title":"Blood Adv."},{"key":"2269_CR14","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bjh.19519","volume":"205","author":"W Jen","year":"2024","unstructured":"Jen, W. et al. Combination therapy with novel agents for acute myeloid leukaemia: insights into treatment of a heterogenous disease. Br. J. Haematol. 205, 30\u201347 (2024).","journal-title":"Br. J. Haematol."},{"key":"2269_CR16","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","volume":"361","author":"B L\u00f6wenberg","year":"2009","unstructured":"L\u00f6wenberg, B. et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 361, 1235\u20131248 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature22993","volume":"547","author":"LI Shlush","year":"2017","unstructured":"Shlush, L. I. et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 547, 104\u2013108 (2017).","journal-title":"Nature"},{"key":"2269_CR18","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/ajh.25162","volume":"93","author":"C Ganzel","year":"2018","unstructured":"Ganzel, C. et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am. J. Hematol. 93, 1074\u20131081 (2018).","journal-title":"Am. J. Hematol."},{"key":"2269_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.trecan.2019.07.009","volume":"5","author":"MT Witkowski","year":"2019","unstructured":"Witkowski, M. T., Lasry, A., Carroll, W. L. & Aifantis, I. Immune-based therapies in acute leukemia. Trends Cancer 5, 604\u2013618 (2019).","journal-title":"Trends Cancer"},{"key":"2269_CR20","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky, I. & Abdul-Hay, M. Acute myeloid leukemia: a comprehensive review and 2016 update\u2019. Blood Cancer J. 6, e441\u2013e441 (2016).","journal-title":"Blood Cancer J."},{"key":"2269_CR21","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","volume":"11","author":"AM Zeidan","year":"2024","unstructured":"Zeidan, A. M. et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 11, e38\u2013e50 (2024).","journal-title":"Lancet Haematol."},{"key":"2269_CR22","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver, N., Alotaibi, A. S., B\u00fccklein, V. & Subklewe, M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia 35, 1843\u20131863 (2021).","journal-title":"Leukemia"},{"key":"2269_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/bloodadvances.2023011721","volume":"8","author":"AA Lane","year":"2024","unstructured":"Lane, A. A. et al. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 8, 591\u2013602 (2024).","journal-title":"Blood Adv."},{"key":"2269_CR24","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","volume":"36","author":"R Ranieri","year":"2022","unstructured":"Ranieri, R. et al. Current status and future perspectives in targeted therapy of NPM1-mutated AML. Leukemia 36, 2351\u20132367 (2022).","journal-title":"Leukemia"},{"key":"2269_CR25","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa, G. C. et al. Therapeutic implications of menin inhibition in acute leukemias. Leukemia 35, 2482\u20132495 (2021).","journal-title":"Leukemia"},{"key":"2269_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR27","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nri2635","volume":"9","author":"CH June","year":"2009","unstructured":"June, C. H., Blazar, B. R. & Riley, J. L. Engineering lymphocyte subsets: tools, trials and tribulations. Nat. Rev. Immunol. 9, 704\u2013716 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"2269_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., Rivi\u00e8re, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423\u2013431 (2017).","journal-title":"Nature"},{"key":"2269_CR29","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu, U., Castelli, S. & June, C. H. CAR T cell combination therapies to treat cancer. Cancer Cell 42, 1319\u20131325 (2024).","journal-title":"Cancer Cell"},{"key":"2269_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","volume":"3","author":"M Hudecek","year":"2015","unstructured":"Hudecek, M. et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3, 125\u2013135 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"2269_CR31","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"MV Maus","year":"2014","unstructured":"Maus, M. V., Grupp, S. A., Porter, D. L. & June, C. H. Antibody derivatives as new therapeutics for hematologic antibody-modified T cells: CARs take the front seat for matologic malignancies. Blood 123, 2625\u20132635 (2014).","journal-title":"Blood"},{"key":"2269_CR32","doi-asserted-by":"publisher","first-page":"755","DOI":"10.4049\/jimmunol.1500751","volume":"195","author":"DM Barrett","year":"2015","unstructured":"Barrett, D. M., Grupp, S. A. & June, C. H. Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. J. Immunol. 195, 755\u2013761 (2015).","journal-title":"J. Immunol."},{"key":"2269_CR33","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"2269_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","volume":"37","author":"S Guedan","year":"2019","unstructured":"Guedan, S., Ruella, M. & June, C. H. Emerging cellular therapies for cancer. Annu. Rev. Immunol. 37, 145\u2013171 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"2269_CR35","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/cancers14030497","volume":"14","author":"J Marvin-Peek","year":"2022","unstructured":"Marvin-Peek, J., Savani, B. N., Olalekan, O. O. & Dholaria, B. Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia. Cancers 14, 497 (2022).","journal-title":"Cancers"},{"key":"2269_CR36","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/s41596-020-0294-8","volume":"15","author":"ZL Chang","year":"2020","unstructured":"Chang, Z. L., Hou, A. J. & Chen, Y. Y. Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands. Nat. Protoc. 15, 1507\u20131524 (2020).","journal-title":"Nat. Protoc."},{"key":"2269_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"2269_CR38","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","volume":"64","author":"BA Irving","year":"1991","unstructured":"Irving, B. A. & Weiss, A. The cytoplasmic domain of the T cell receptor chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891\u2013901 (1991).","journal-title":"Cell"},{"key":"2269_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrc971","volume":"3","author":"M Sadelain","year":"2003","unstructured":"Sadelain, M., Rivi\u00e8re, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35\u201345 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"2269_CR40","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","volume":"96","author":"T Brocker","year":"2000","unstructured":"Brocker, T. Chimeric Fv-\u03b6 or Fv-\u03b5 receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96, 1999\u20132001 (2000).","journal-title":"Blood"},{"key":"2269_CR41","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"CHJ Lamers","year":"2006","unstructured":"Lamers, C. H. J. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20\u2013e22 (2006).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR42","doi-asserted-by":"publisher","first-page":"6577","DOI":"10.4049\/jimmunol.151.11.6577","volume":"151","author":"I Stancovski","year":"1993","unstructured":"Stancovski, I. et al. Targeting of T lymphocytes to Neu\/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151, 6577\u20136582 (1993).","journal-title":"J. Immunol."},{"key":"2269_CR43","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1073\/pnas.91.10.4318","volume":"91","author":"D Moritz","year":"1994","unstructured":"Moritz, D., Wels, W., Mattern, J. & Groner, B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl. Acad. Sci. USA 91, 4318\u20134322 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2269_CR44","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106\u20136115 (2006).","journal-title":"Clin. Cancer Res."},{"key":"2269_CR45","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90, 720\u2013724 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2269_CR46","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain, M., Brentjens, R. & Rivi\u00e8re, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388\u2013398 (2013).","journal-title":"Cancer Discov."},{"key":"2269_CR47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227\u2013242 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"2269_CR48","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1182\/blood-2002-04-1041","volume":"100","author":"NM Haynes","year":"2002","unstructured":"Haynes, N. M. et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100, 3155\u20133163 (2002).","journal-title":"Blood"},{"key":"2269_CR49","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.leu.2403302","volume":"18","author":"C Imai","year":"2004","unstructured":"Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676\u2013684 (2004).","journal-title":"Leukemia"},{"key":"2269_CR50","doi-asserted-by":"crossref","unstructured":"Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3, e96976 (2018).","DOI":"10.1172\/jci.insight.96976"},{"key":"2269_CR51","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/onci.19855","volume":"1","author":"AA Hombach","year":"2012","unstructured":"Hombach, A. A., Heiders, J., Foppe, M., Chmielewski, M. & Abken, H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4 + T cells. Oncoimmunology 1, 458\u2013466 (2012).","journal-title":"Oncoimmunology"},{"key":"2269_CR52","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1038\/s41375-019-0417-9","volume":"33","author":"MR Collinson-Pautz","year":"2019","unstructured":"Collinson-Pautz, M. R. et al. Constitutively active MyD88\/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia 33, 2195\u20132207 (2019).","journal-title":"Leukemia"},{"key":"2269_CR53","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski, M. & Abken, H. TRUCKs: the fourth generation of CARs. Expert Opin. Biol. Ther. 15, 1145\u20131154 (2015).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2269_CR54","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.molmed.2017.03.002","volume":"23","author":"ZL Chang","year":"2017","unstructured":"Chang, Z. L. & Chen, Y. Y. CARs: synthetic immunoreceptors for cancer therapy and beyond. Trends Mol. Med. 23, 430\u2013450 (2017).","journal-title":"Trends Mol. Med."},{"key":"2269_CR55","doi-asserted-by":"crossref","unstructured":"Cappell, K.M. & Kochenderfer, J.N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","DOI":"10.1038\/s41571-023-00754-1"},{"key":"2269_CR56","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724\u2013740 (2017).","journal-title":"Cell"},{"key":"2269_CR57","doi-asserted-by":"crossref","unstructured":"Falg\u00e0s, A. et al. A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B cell acute lymphoblastic leukemia. [Manuscript submitted for publication]. Blood (2025).","DOI":"10.1182\/blood.2024025440"},{"key":"2269_CR58","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong, M., Clubb, J. D. & Chen, Y. Y. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell 38, 473\u2013488 (2020).","journal-title":"Cancer Cell"},{"key":"2269_CR59","doi-asserted-by":"crossref","unstructured":"Asmamaw Dejenie, T. et al. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum. Vaccin. Immunother. 18, 2036528 (2022).","DOI":"10.1080\/21645515.2022.2114254"},{"key":"2269_CR60","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew, N., Ogonek, J., Endres, S., von Bergwelt-Baildon, M. & Kobold, S. Teaching an old dog new tricks: next-generation CAR T cells. Br. J. Cancer 120, 26\u201337 (2019).","journal-title":"Br. J. Cancer"},{"key":"2269_CR61","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects. Nat. Med. 24, 352\u2013359 (2018).","journal-title":"Nat. Med."},{"key":"2269_CR62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","volume":"4","author":"D Li","year":"2019","unstructured":"Li, D. et al. Genetically engineered T cells for cancer immunotherapy. Signal Transduct. Target Ther. 4, 35 (2019).","journal-title":"Signal Transduct. Target Ther."},{"key":"2269_CR63","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 609, 369\u2013374 (2022).","journal-title":"Nature"},{"key":"2269_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp, L. J. et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci. Rep. 7, 737 (2017).","journal-title":"Sci. Rep."},{"key":"2269_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson, C. A. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 23, 91\u2013103 (2022).","journal-title":"Lancet Oncol."},{"key":"2269_CR66","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR67","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2269_CR68","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","volume":"2","author":"L Labanieh","year":"2018","unstructured":"Labanieh, L., Majzner, R. G. & Mackall, C. L. Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2, 377\u2013391 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"2269_CR69","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(61)90693-6","volume":"2","author":"JF Miller","year":"1961","unstructured":"Miller, J. F. Immunological function of the thymus. Lancet 2, 748\u2013749 (1961).","journal-title":"Lancet"},{"key":"2269_CR70","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/191248a0","volume":"191","author":"JF Miller","year":"1961","unstructured":"Miller, J. F. Analysis of the thymus influence in leukaemogenesis. Nature 191, 248\u2013249 (1961).","journal-title":"Nature"},{"key":"2269_CR71","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1158\/2326-6066.CIR-17-0112","volume":"5","author":"OJ Finn","year":"2017","unstructured":"Finn, O. J. Human tumor antigens yesterday, today, and tomorrow. Cancer Immunol. Res 5, 347\u2013354 (2017).","journal-title":"Cancer Immunol. Res"},{"key":"2269_CR72","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318\u20131321 (1986).","journal-title":"Science"},{"key":"2269_CR73","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676\u20131680 (1988).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR74","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","volume":"86","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg, S. A. et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86, 1159\u20131166 (1994).","journal-title":"J. Natl Cancer Inst."},{"key":"2269_CR75","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","volume":"149","author":"Y Kuwana","year":"1987","unstructured":"Kuwana, Y. et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem. Biophys. Res Commun. 149, 960\u2013968 (1987).","journal-title":"Biochem. Biophys. Res Commun."},{"key":"2269_CR76","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA 86, 10024\u201310028 (1989).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2269_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26683-0","volume":"12","author":"N El Khawanky","year":"2021","unstructured":"El Khawanky, N. et al. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat. Commun. 12, 6436 (2021).","journal-title":"Nat. Commun."},{"key":"2269_CR78","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","volume":"5","author":"KM Hege","year":"2017","unstructured":"Hege, K. M. et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J. Immunother. Cancer 5, 22 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"2269_CR79","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1182\/blood.V90.3.952","volume":"90","author":"HF Gallardo","year":"1997","unstructured":"Gallardo, H. F., Tan, C., Ory, D. & Sadelain, M. Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90, 952\u2013957 (1997).","journal-title":"Blood"},{"key":"2269_CR80","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1084\/jem.188.4.619","volume":"188","author":"A Krause","year":"1998","unstructured":"Krause, A. et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med 188, 619\u2013626 (1998).","journal-title":"J. Exp. Med"},{"key":"2269_CR81","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1073\/pnas.86.4.1333","volume":"86","author":"CB Thompson","year":"1989","unstructured":"Thompson, C. B. et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines\/cytokines. Proc. Natl. Acad. Sci. USA 86, 1333\u20131337 (1989).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2269_CR82","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher, J., Brentjens, R. J., Gunset, G., Rivi\u00e8re, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor. Nat. Biotechnol. 20, 70\u201375 (2002).","journal-title":"Nat. Biotechnol."},{"key":"2269_CR83","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","volume":"161","author":"HM Finney","year":"1998","unstructured":"Finney, H. M., Lawson, A. D., Bebbington, C. R. & Weir, A. N. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161, 2791\u20132797 (1998).","journal-title":"J. Immunol."},{"key":"2269_CR84","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nm827","volume":"9","author":"RJ Brentjens","year":"2003","unstructured":"Brentjens, R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med 9, 279\u2013286 (2003).","journal-title":"Nat. Med"},{"key":"2269_CR85","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","volume":"24","author":"V Hoyos","year":"2010","unstructured":"Hoyos, V. et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety. Leukemia 24, 1160\u20131170 (2010).","journal-title":"Leukemia"},{"key":"2269_CR86","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","volume":"32","author":"JN Kochenderfer","year":"2009","unstructured":"Kochenderfer, J. N. et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32, 689\u2013702 (2009).","journal-title":"J. Immunother."},{"key":"2269_CR87","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453\u20131464 (2009).","journal-title":"Mol. Ther."},{"key":"2269_CR88","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","volume":"32","author":"D Hollyman","year":"2009","unstructured":"Hollyman, D. et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32, 169\u2013180 (2009).","journal-title":"J. Immunother."},{"key":"2269_CR89","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/mt.2011.1","volume":"19","author":"DB Kohn","year":"2011","unstructured":"Kohn, D. B. et al. CARs on track in the clinic. Mol. Ther. 19, 432\u2013438 (2011).","journal-title":"Mol. Ther."},{"key":"2269_CR90","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099\u20134102 (2010).","journal-title":"Blood"},{"key":"2269_CR91","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med 3, 95ra73 (2011).","journal-title":"Sci. Transl. Med"},{"key":"2269_CR92","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med"},{"key":"2269_CR93","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817\u20134828 (2011).","journal-title":"Blood"},{"key":"2269_CR94","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).","journal-title":"Sci. Transl. Med."},{"key":"2269_CR95","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med 368, 1509\u20131518 (2013).","journal-title":"N. Engl. J. Med"},{"key":"2269_CR96","unstructured":"Schneider, M. Carl June, first year Emily Whitehead reflect on experiences with Penn-pioneered cancer treatment. The Daily Pennsylvanian (2024)."},{"key":"2269_CR97","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain, M. D., Smith, M. & Shah, N. N. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 141, 2430\u20132442 (2023).","journal-title":"Blood"},{"key":"2269_CR98","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","volume":"15","author":"C Kotch","year":"2019","unstructured":"Kotch, C., Barrett, D. & Teachey, D. T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev. Clin. Immunol. 15, 813\u2013822 (2019).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"2269_CR99","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccc.2022.09.004","volume":"39","author":"J Romano","year":"2023","unstructured":"Romano, J., Wilsterman, E., Toal, M. & Joyce, C. Cytokine Release Syndrome in the Pediatric Population and Implications for Intensive Care Management. Crit. Care Clin. 39, 277\u2013285 (2023).","journal-title":"Crit. Care Clin."},{"key":"2269_CR100","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jtct.2023.10.006","volume":"30","author":"KO McNerney","year":"2024","unstructured":"McNerney, K. O. et al. INSPIRED symposium part 3: prevention and management of pediatric chimeric antigen receptor T Cell-associated emergent toxicities. Transpl. Cell Ther. 30, 38\u201355 (2024).","journal-title":"Transpl. Cell Ther."},{"key":"2269_CR101","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med"},{"key":"2269_CR102","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR103","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709\u20132720 (2012).","journal-title":"Blood"},{"key":"2269_CR104","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2269_CR105","unstructured":"University of Pennsylvania. University of Pennsylvania and Novartis Form Alliance to Expand Use of Personalized T Cell Therapy for Cancer Patients. University of Pennsylvania and Penn Medicine announce breakthrough in the treatment of a rare genetic disease. Penn Medicine https:\/\/www.pennmedicine.org\/news\/news-releases\/2012\/august\/university-of-pennsylvania-and (2012)."},{"key":"2269_CR106","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nbt0113-10a","volume":"31","author":"M Costandi","year":"2013","unstructured":"Costandi, M. Kite and NCI partner on T cells. Nat. Biotechnol. 31, 10\u201310 (2013).","journal-title":"Nat. Biotechnol."},{"key":"2269_CR107","unstructured":"Memorial Sloan Kettering Cancer Center. New biotech startup will pit immune system against cancer with cutting-edge gene therapy. Memorial Sloan Kettering Cancer Center https:\/\/www.mskcc.org\/news\/new-biotech-startup-will-pit-immune-system-against (2020)."},{"key":"2269_CR108","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jcyt.2019.12.004","volume":"22","author":"P Braendstrup","year":"2020","unstructured":"Braendstrup, P., Levine, B. L. & Ruella, M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy 22, 57\u201369 (2020).","journal-title":"Cytotherapy"},{"key":"2269_CR109","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR110","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR111","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler, N. H. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat. Med. 28, 325\u2013332 (2022).","journal-title":"Nat. Med."},{"key":"2269_CR112","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR113","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"2269_CR114","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2021014892","volume":"140","author":"NV Frey","year":"2022","unstructured":"Frey, N. V. Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia. Blood 140, 11\u201315 (2022).","journal-title":"Blood"},{"key":"2269_CR115","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/oncolo\/oyac163","volume":"27","author":"N Bouchkouj","year":"2022","unstructured":"Bouchkouj, N. et al. FDA approval summary: brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Oncologist 27, 892\u2013899 (2022).","journal-title":"Oncologist"},{"key":"2269_CR116","doi-asserted-by":"publisher","first-page":"8040","DOI":"10.1200\/JCO.2020.38.15_suppl.8040","volume":"38","author":"AR Sehgal","year":"2020","unstructured":"Sehgal, A. R. et al. Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed\/refractory (R\/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study. J. Clin. Oncol. 38, 8040\u20138040 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR117","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"2269_CR118","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR119","doi-asserted-by":"crossref","unstructured":"Chekol Abebe, E., Yibeltal Shiferaw, M., Tadele Admasu, F. & Asmamaw Dejenie, T. Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front. Immunol. 13, 1007515 (2022).","DOI":"10.3389\/fimmu.2022.991092"},{"key":"2269_CR120","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2022","unstructured":"Martin, T. et al. Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265\u20131274 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR121","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan, V. et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 28, 724\u2013734 (2022).","journal-title":"Nat. Med."},{"key":"2269_CR122","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas, A. R. et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol. Ther. 27, 1919\u20131929 (2019).","journal-title":"Mol. Ther."},{"key":"2269_CR123","doi-asserted-by":"crossref","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaag3518 (2017).","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"2269_CR124","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR125","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"2269_CR126","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189\u20131198 (2022).","journal-title":"Nat. Med."},{"key":"2269_CR127","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR128","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N., Maus, M. V. & Hinrichs, C. S. CAR T-cells and T-cell therapies for cancer: a translational science review. JAMA 332, 1924\u20131935 (2024).","journal-title":"JAMA"},{"key":"2269_CR129","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo, S. P. et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 403, 1460\u20131471 (2024).","journal-title":"Lancet"},{"key":"2269_CR130","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","volume":"41","author":"SM Norberg","year":"2023","unstructured":"Norberg, S. M. & Hinrichs, C. S. Engineered T cell therapy for viral and non-viral epithelial cancers. Cancer Cell 41, 58\u201369 (2023).","journal-title":"Cancer Cell"},{"key":"2269_CR131","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","volume":"27","author":"NB Nagarsheth","year":"2021","unstructured":"Nagarsheth, N. B. et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat. Med. 27, 419\u2013425 (2021).","journal-title":"Nat. Med."},{"key":"2269_CR132","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1200\/JCO.18.02424","volume":"37","author":"SL Doran","year":"2019","unstructured":"Doran, S. L. et al. T-cell receptor gene therapy for human papillomavirus\u2013associated epithelial cancers: a first-in-human, phase I\/II study. J. Clin. Oncol. 37, 2759\u20132768 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR133","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.stemcr.2017.04.019","volume":"8","author":"R Diaz de la Guardia","year":"2017","unstructured":"Diaz de la Guardia, R. et al. Detailed characterization of mesenchymal stem\/stromal cells from a large cohort of aml patients demonstrates a definitive link to treatment outcomes. Stem Cell Rep. 8, 1573\u20131586 (2017).","journal-title":"Stem Cell Rep."},{"key":"2269_CR134","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1097\/HS9.0000000000000937","volume":"7","author":"J Vanhooren","year":"2023","unstructured":"Vanhooren, J. et al. CAR-T in the treatment of acute myeloid leukemia: barriers and how to overcome them. Hemasphere 7, e937 (2023).","journal-title":"Hemasphere"},{"key":"2269_CR135","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","volume":"368","author":"E Estey","year":"2006","unstructured":"Estey, E. & D\u00f6hner, H. Acute myeloid leukaemia. Lancet 368, 1894\u20131907 (2006).","journal-title":"Lancet"},{"key":"2269_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106727","volume":"111","author":"D Padmakumar","year":"2021","unstructured":"Padmakumar, D. et al. A concise review on the molecular genetics of acute myeloid leukemia. Leuk. Res 111, 106727 (2021).","journal-title":"Leuk. Res"},{"key":"2269_CR137","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1182\/blood.2021014670","volume":"141","author":"A Ediriwickrema","year":"2023","unstructured":"Ediriwickrema, A., Gentles, A. J. & Majeti, R. Single-cell genomics in AML: extending the frontiers of AML research. Blood 141, 345\u2013355 (2023).","journal-title":"Blood"},{"key":"2269_CR138","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury, J. D. et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36, 1703\u20131719 (2022).","journal-title":"Leukemia"},{"key":"2269_CR139","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"2269_CR140","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber, D. A. et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140, 1200\u20131228 (2022).","journal-title":"Blood"},{"key":"2269_CR141","doi-asserted-by":"crossref","unstructured":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059\u20132074 (2013).","DOI":"10.1056\/NEJMoa1301689"},{"key":"2269_CR142","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730\u2013737 (1997).","journal-title":"Nat. Med."},{"key":"2269_CR143","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1001\/jama.2010.1862","volume":"304","author":"AJ Gentles","year":"2010","unstructured":"Gentles, A. J. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 304, 2706 (2010).","journal-title":"JAMA"},{"key":"2269_CR144","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","volume":"129","author":"D Thomas","year":"2017","unstructured":"Thomas, D. & Majeti, R. Biology and relevance of human acute myeloid leukemia stem cells. Blood 129, 1577\u20131585 (2017).","journal-title":"Blood"},{"key":"2269_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19119-8","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita, K. et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat. Commun. 11, 5327 (2020).","journal-title":"Nat. Commun."},{"key":"2269_CR146","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.2415","volume":"17","author":"K Eppert","year":"2011","unstructured":"Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17, 1086\u20131093 (2011).","journal-title":"Nat. Med."},{"key":"2269_CR147","doi-asserted-by":"publisher","first-page":"20117","DOI":"10.1073\/pnas.2003900117","volume":"117","author":"L Jiang","year":"2020","unstructured":"Jiang, L. et al. Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome. Proc. Natl. Acad. Sci. USA117, 20117\u201320126 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2269_CR148","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"AM Paczulla","year":"2019","unstructured":"Paczulla, A. M. et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature 572, 254\u2013259 (2019).","journal-title":"Nature"},{"key":"2269_CR149","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00277-011-1231-2","volume":"90","author":"M Rickmann","year":"2011","unstructured":"Rickmann, M. et al. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Ann. Hematol. 90, 1047\u20131058 (2011).","journal-title":"Ann. Hematol."},{"key":"2269_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/srep32428","volume":"6","author":"J-Y Chen","year":"2016","unstructured":"Chen, J.-Y. et al. The oncometabolite R-2-hydroxyglutarate activates NF-\u03baB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells. Sci. Rep. 6, 32428 (2016).","journal-title":"Sci. Rep."},{"key":"2269_CR151","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature11323","volume":"488","author":"M Sasaki","year":"2012","unstructured":"Sasaki, M. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488, 656\u2013659 (2012).","journal-title":"Nature"},{"key":"2269_CR152","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1182\/blood.2023020731","volume":"143","author":"T Brummer","year":"2024","unstructured":"Brummer, T. & Zeiser, R. The role of the MDM2\/p53 axis in antitumor immune responses. Blood 143, 2701\u20132709 (2024).","journal-title":"Blood"},{"key":"2269_CR153","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","volume":"12","author":"NG Daver","year":"2022","unstructured":"Daver, N. G. et al. TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions. Cancer Discov. 12, 2516\u20132529 (2022).","journal-title":"Cancer Discov."},{"key":"2269_CR154","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/cells12030512","volume":"12","author":"K Voskarides","year":"2023","unstructured":"Voskarides, K. & Giannopoulou, N. The role of TP53 in adaptation and evolution. Cells 12, 512 (2023).","journal-title":"Cells"},{"key":"2269_CR155","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/leu.2016.144","volume":"30","author":"SR McCurdy","year":"2016","unstructured":"McCurdy, S. R. et al. Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. Leukemia 30, 2102\u20132106 (2016).","journal-title":"Leukemia"},{"key":"2269_CR156","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/leu.2014.314","volume":"29","author":"L Crucitti","year":"2015","unstructured":"Crucitti, L. et al. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia 29, 1143\u20131152 (2015).","journal-title":"Leukemia"},{"key":"2269_CR157","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMoa0811036","volume":"361","author":"L Vago","year":"2009","unstructured":"Vago, L. et al. Loss of mismatched HLA in Leukemia after stem-cell transplantation. N. Engl. J. Med. 361, 478\u2013488 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR158","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cytogfr.2018.08.004","volume":"43","author":"S Binder","year":"2018","unstructured":"Binder, S., Luciano, M. & Horejs-Hoeck, J. The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev. 43, 8\u201315 (2018).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2269_CR159","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/10428194.2011.603446","volume":"53","author":"Y Wu","year":"2012","unstructured":"Wu, Y., Chen, P., Huang, H.-F., Huang, M.-J. & Chen, Y.-Z. Reduction of transforming growth factor-\u03b21 expression in leukemia and its possible role in leukemia development. Leuk. Lymphoma 53, 145\u2013151 (2012).","journal-title":"Leuk. Lymphoma"},{"key":"2269_CR160","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","volume":"30","author":"AS Bhagwat","year":"2024","unstructured":"Bhagwat, A. S. et al. Cytokine-mediated CAR T therapy resistance in AML. Nat. Med. 30, 3697\u20133708 (2024).","journal-title":"Nat. Med."},{"key":"2269_CR161","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029\u20131033 (2009).","journal-title":"Science"},{"key":"2269_CR162","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","volume":"122","author":"F Mussai","year":"2013","unstructured":"Mussai, F. et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood 122, 749\u2013758 (2013).","journal-title":"Blood"},{"key":"2269_CR163","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","volume":"36","author":"S Tettamanti","year":"2022","unstructured":"Tettamanti, S., Pievani, A., Biondi, A., Dotti, G. & Serafini, M. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia 36, 13\u201322 (2022).","journal-title":"Leukemia"},{"key":"2269_CR164","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood.2022018092","volume":"141","author":"SK Mishra","year":"2023","unstructured":"Mishra, S. K., Millman, S. E. & Zhang, L. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood 141, 1119\u20131135 (2023).","journal-title":"Blood"},{"key":"2269_CR165","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ccell.2023.02.009","volume":"41","author":"L van Vlerken-Ysla","year":"2023","unstructured":"van Vlerken-Ysla, L., Tyurina, Y. Y., Kagan, V. E. & Gabrilovich, D. I. Functional states of myeloid cells in cancer. Cancer Cell 41, 490\u2013504 (2023).","journal-title":"Cancer Cell"},{"key":"2269_CR166","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich, D. I. Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3\u20138 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"2269_CR167","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485\u2013498 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"2269_CR168","doi-asserted-by":"publisher","unstructured":"Guo, M. et al. Core binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis. Blood https:\/\/doi.org\/10.1182\/blood.2022015830 (2023).","DOI":"10.1182\/blood.2022015830"},{"key":"2269_CR169","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.ccell.2021.04.017","volume":"39","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. N6-methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation. Cancer Cell 39, 958\u2013972.e8 (2021).","journal-title":"Cancer Cell"},{"key":"2269_CR170","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/10428194.2015.1041388","volume":"57","author":"R Mabuchi","year":"2016","unstructured":"Mabuchi, R. et al. High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia. Leuk. Lymphoma 57, 92\u201398 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"2269_CR171","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","volume":"15","author":"IM Ghobrial","year":"2018","unstructured":"Ghobrial, I. M., Detappe, A., Anderson, K. C. & Steensma, D. P. The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat. Rev. Clin. Oncol. 15, 219\u2013233 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2269_CR172","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.3390\/cells10123376","volume":"10","author":"F Hao","year":"2021","unstructured":"Hao, F., Sholy, C., Wang, C., Cao, M. & Kang, X. The role of t cell immunotherapy in acute myeloid leukemia. Cells 10, 3376 (2021).","journal-title":"Cells"},{"key":"2269_CR173","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1111\/cas.15932","volume":"114","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. Single-cell RNA-seq reveals a microenvironment and an exhaustion state of T\/NK cells in acute myeloid leukemia. Cancer Sci. 114, 3873\u20133883 (2023).","journal-title":"Cancer Sci."},{"key":"2269_CR174","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1182\/blood.2023019961","volume":"143","author":"J Vadakekolathu","year":"2024","unstructured":"Vadakekolathu, J. & Rutella, S. Escape from T-cell\u2013targeting immunotherapies in acute myeloid leukemia. Blood 143, 2689\u20132700 (2024).","journal-title":"Blood"},{"key":"2269_CR175","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08871-1","volume":"10","author":"M Noviello","year":"2019","unstructured":"Noviello, M. et al. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat. Commun. 10, 1065 (2019).","journal-title":"Nat. Commun."},{"key":"2269_CR176","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00277-017-3051-5","volume":"96","author":"F Haroun","year":"2017","unstructured":"Haroun, F., Solola, S. A., Nassereddine, S. & Tabbara, I. PD-1 signaling and inhibition in AML and MDS. Ann. Hematol. 96, 1441\u20131448 (2017).","journal-title":"Ann. Hematol."},{"key":"2269_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26282-z","volume":"12","author":"HA Abbas","year":"2021","unstructured":"Abbas, H. A. et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat. Commun. 12, 6071 (2021).","journal-title":"Nat. Commun."},{"key":"2269_CR178","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1158\/2326-6066.CIR-17-0212","volume":"6","author":"T Nuebling","year":"2018","unstructured":"Nuebling, T. et al. The immune checkpoint modulator OX40 and its ligand OX40L in NK-cell immunosurveillance and acute myeloid leukemia. Cancer Immunol. Res. 6, 209\u2013221 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"2269_CR179","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.3390\/cancers15102713","volume":"15","author":"E Atilla","year":"2023","unstructured":"Atilla, E. & Benabdellah, K. The black hole: CAR T cell therapy in AML. Cancers15, 2713 (2023).","journal-title":"Cancers"},{"key":"2269_CR180","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41586-019-1104-8","volume":"569","author":"AN Tikhonova","year":"2019","unstructured":"Tikhonova, A. N. et al. The bone marrow microenvironment at single-cell resolution. Nature 569, 222\u2013228 (2019).","journal-title":"Nature"},{"key":"2269_CR181","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI125423","volume":"129","author":"OC Finney","year":"2019","unstructured":"Finney, O. C. et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J. Clin. Investig. 129, 2123\u20132132 (2019).","journal-title":"J. Clin. Investig."},{"key":"2269_CR182","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"2269_CR183","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ejh.12228","volume":"92","author":"H Kr\u00f6nig","year":"2014","unstructured":"Kr\u00f6nig, H. et al. Interferon-induced programmed death-ligand 1 (PD-L1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur. J. Haematol. 92, 195\u2013203 (2014).","journal-title":"Eur. J. Haematol."},{"key":"2269_CR184","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","volume":"184","author":"CR Good","year":"2021","unstructured":"Good, C. R. et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184, 6081\u20136100.e26 (2021).","journal-title":"Cell"},{"key":"2269_CR185","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"2269_CR186","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3324\/haematol.2016.143180","volume":"101","author":"YS Al-Matary","year":"2016","unstructured":"Al-Matary, Y. S. et al. Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner. Haematologica 101, 1216\u20131227 (2016).","journal-title":"Haematologica"},{"key":"2269_CR187","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"C Toffalori","year":"2019","unstructured":"Toffalori, C. et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat. Med. 25, 603\u2013611 (2019).","journal-title":"Nat. Med."},{"key":"2269_CR188","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0069-4","volume":"8","author":"B Jia","year":"2018","unstructured":"Jia, B. et al. Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. Blood Cancer J. 8, 34 (2018).","journal-title":"Blood Cancer J."},{"key":"2269_CR189","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","volume":"114","author":"R Le Dieu","year":"2009","unstructured":"Le Dieu, R. et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 114, 3909\u20133916 (2009).","journal-title":"Blood"},{"key":"2269_CR190","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.leu.2404032","volume":"20","author":"D Behl","year":"2006","unstructured":"Behl, D. et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 20, 29\u201334 (2006).","journal-title":"Leukemia"},{"key":"2269_CR191","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/2643-3230.BCD-23-0202","volume":"5","author":"C Restelli","year":"2024","unstructured":"Restelli, C. et al. Recent advances in immune-based therapies for acute myeloid leukemia. Blood Cancer Discov. 5, 234\u2013248 (2024).","journal-title":"Blood Cancer Discov."},{"key":"2269_CR192","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.cell.2019.04.040","volume":"177","author":"N Baryawno","year":"2019","unstructured":"Baryawno, N. et al. A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. Cell 177, 1915\u20131932.e16 (2019).","journal-title":"Cell"},{"key":"2269_CR193","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","volume":"41","author":"S Haubner","year":"2023","unstructured":"Haubner, S. et al. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell 41, 1871\u20131891.e6 (2023).","journal-title":"Cancer Cell"},{"key":"2269_CR194","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"2269_CR195","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/mt.2013.154","volume":"21","author":"DS Ritchie","year":"2013","unstructured":"Ritchie, D. S. et al. Persistence and efficacy of second generation CAR T cell against the ley antigen in acute myeloid leukemia. Mol. Ther. 21, 2122\u20132129 (2013).","journal-title":"Mol. Ther."},{"key":"2269_CR196","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341\u20131355 (2019).","journal-title":"Nat. Med."},{"key":"2269_CR197","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","volume":"14","author":"C Jordan","year":"2000","unstructured":"Jordan, C. et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777\u20131784 (2000).","journal-title":"Leukemia"},{"key":"2269_CR198","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner, S. et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia 33, 64\u201374 (2019).","journal-title":"Leukemia"},{"key":"2269_CR199","doi-asserted-by":"crossref","unstructured":"Schorr, C. & Perna, F. Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia. Front. Immunol. 13, 1085978 (2022).","DOI":"10.3389\/fimmu.2022.1085978"},{"key":"2269_CR200","first-page":"1261","volume":"86","author":"L Munoz","year":"2001","unstructured":"Munoz, L. et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 86, 1261\u20131269 (2001).","journal-title":"Haematologica"},{"key":"2269_CR201","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/ijms24032718","volume":"24","author":"E Pelosi","year":"2023","unstructured":"Pelosi, E., Castelli, G. & Testa, U. CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm. Int. J. Mol. Sci. 24, 2718 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2269_CR202","doi-asserted-by":"publisher","first-page":"e000845","DOI":"10.1136\/jitc-2020-000845","volume":"8","author":"ML Baroni","year":"2020","unstructured":"Baroni, M. L. et al. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. J. Immunother. Cancer 8, e000845 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2269_CR203","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","volume":"124","author":"AE Frankel","year":"2014","unstructured":"Frankel, A. E. et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 124, 385\u2013392 (2014).","journal-title":"Blood"},{"key":"2269_CR204","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/10428190701799035","volume":"49","author":"A Frankel","year":"2008","unstructured":"Frankel, A., Liu, J.-S., Rizzieri, D. & Hogge, D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk. Lymphoma 49, 543\u2013553 (2008).","journal-title":"Leuk. Lymphoma"},{"key":"2269_CR205","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3109\/10428194.2014.956316","volume":"56","author":"SZ He","year":"2015","unstructured":"He, S. Z. et al. A phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk. Lymphoma 56, 1406\u20131415 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"2269_CR206","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","volume":"35","author":"P Montesinos","year":"2021","unstructured":"Montesinos, P. et al. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study. Leukemia 35, 62\u201374 (2021).","journal-title":"Leukemia"},{"key":"2269_CR207","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"P Naveen","year":"2019","unstructured":"Naveen, P. et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N. Engl. J. Med. 380, 1628\u20131637 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR208","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1182\/blood-2021-147486","volume":"138","author":"AA Lane","year":"2021","unstructured":"Lane, A. A. et al. Safety and efficacy of combining tagraxofusp (SL-401) with azacitidine or azacitidine and venetoclax in a phase 1b study for CD123 positive AML, MDS, or BPDCN. Blood 138, 2346\u20132346 (2021).","journal-title":"Blood"},{"key":"2269_CR209","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood-2019-128648","volume":"134","author":"NG Daver","year":"2019","unstructured":"Daver, N. G. et al. Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood 134, 734\u2013734 (2019).","journal-title":"Blood"},{"key":"2269_CR210","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1182\/blood-2022-158030","volume":"140","author":"N Daver","year":"2022","unstructured":"Daver, N. et al. Broad activity for the pivekimab sunirine (PVEK, IMGN632), azacitidine, and venetoclax triplet in high-risk patients with relapsed\/refractory acute myeloid leukemia (AML). Blood 140, 145\u2013149 (2022).","journal-title":"Blood"},{"key":"2269_CR211","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-134746","volume":"136","author":"F Ravandi","year":"2020","unstructured":"Ravandi, F. et al. Complete responses in relapsed\/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific antibody; initial results of a phase 1 study. Blood 136, 4\u20135 (2020).","journal-title":"Blood"},{"key":"2269_CR212","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2019-128485","volume":"134","author":"JE Godwin","year":"2019","unstructured":"Godwin, J. E. et al. Flotetuzumab (FLZ), an investigational CD123 x CD3 bispecific dart\u00ae protein-induced clustering of CD3+ T cells and CD123+ AML cells in bone marrow biopsies is associated with response to treatment in primary refractory AML patients. Blood 134, 1410 (2019).","journal-title":"Blood"},{"key":"2269_CR213","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/blood.2020007732","volume":"137","author":"GL Uy","year":"2021","unstructured":"Uy, G. L. et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood 137, 751\u2013762 (2021).","journal-title":"Blood"},{"key":"2269_CR214","doi-asserted-by":"publisher","first-page":"11753","DOI":"10.1182\/blood-2022-159524","volume":"140","author":"ES Winer","year":"2022","unstructured":"Winer, E. S. et al. A phase 1, first-in-human, dose-escalation study of MGD024, a CD123 x CD3 bispecific dart\u00ae molecule, in patients with relapsed or refractory CD123-positive (+) hematologic malignancies. Blood 140, 11753\u201311754 (2022).","journal-title":"Blood"},{"key":"2269_CR215","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1365-2141.2009.08033.x","volume":"148","author":"C Stein","year":"2010","unstructured":"Stein, C. et al. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br. J. Haematol. 148, 879\u2013889 (2010).","journal-title":"Br. J. Haematol."},{"key":"2269_CR216","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1038\/bcj.2014.39","volume":"4","author":"A Ehninger","year":"2014","unstructured":"Ehninger, A. et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 4, e218\u2013e218 (2014).","journal-title":"Blood Cancer J."},{"key":"2269_CR217","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1182\/blood.V67.4.1048.1048","volume":"67","author":"P Dinndorf","year":"1986","unstructured":"Dinndorf, P. et al. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67, 1048\u20131053 (1986).","journal-title":"Blood"},{"key":"2269_CR218","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","volume":"119","author":"RB Walter","year":"2012","unstructured":"Walter, R. B., Appelbaum, F. R., Estey, E. H. & Bernstein, I. D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 119, 6198\u20136208 (2012).","journal-title":"Blood"},{"key":"2269_CR219","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne, S. et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379, 1508\u20131516 (2012).","journal-title":"Lancet"},{"key":"2269_CR220","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett, A. K. et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J. Clin. Oncol. 29, 369\u2013377 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR221","unstructured":"FDA. MYLOTARGTM (Gemtuzumab Ozogamicin) for Injection. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761060lbl.pdf (accessed on 1 Sep 2024)."},{"key":"2269_CR222","unstructured":"EMA. EPAR\u2014Summary for Mylotarg\u2014Epar Product Information Public. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mylotarg-epar-product-information_en.pdf (accessed on 1 Sep 2024)."},{"key":"2269_CR223","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","volume":"23","author":"KJ Norsworthy","year":"2018","unstructured":"Norsworthy, K. J. et al. FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. Oncologist 23, 1103\u20131108 (2018).","journal-title":"Oncologist"},{"key":"2269_CR224","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2019002779","volume":"135","author":"X He","year":"2020","unstructured":"He, X. et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood 135, 713\u2013723 (2020).","journal-title":"Blood"},{"key":"2269_CR225","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1182\/blood-2017-01-762419","volume":"129","author":"CD Godwin","year":"2017","unstructured":"Godwin, C. D., McDonald, G. B. & Walter, R. B. Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood 129, 2330\u20132332 (2017).","journal-title":"Blood"},{"key":"2269_CR226","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","volume":"99","author":"P Rajvanshi","year":"2002","unstructured":"Rajvanshi, P., Shulman, H. M., Sievers, E. L. & McDonald, G. B. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (mylotarg) therapy. Blood 99, 2310\u20132314 (2002).","journal-title":"Blood"},{"key":"2269_CR227","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1182\/blood-2022-157588","volume":"140","author":"GJ Schiller","year":"2022","unstructured":"Schiller, G. J. et al. Early clinical evaluation of potential synergy of targeted radiotherapy with lintuzumab-Ac225 and venetoclax in relapsed\/refractory AML. Blood 140, 3336\u20133337 (2022).","journal-title":"Blood"},{"key":"2269_CR228","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2022-157827","volume":"140","author":"S Abedin","year":"2022","unstructured":"Abedin, S. et al. Lintuzumab-Ac225 with combination with intensive chemotherapy yields high response rate and MRD negativity in R\/R AML with adverse features. Blood 140, 157\u2013158 (2022).","journal-title":"Blood"},{"key":"2269_CR229","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","volume":"23","author":"EJ Feldman","year":"2005","unstructured":"Feldman, E. J. et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J. Clin. Oncol. 23, 4110\u20134116 (2005).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR230","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","volume":"131","author":"EM Stein","year":"2018","unstructured":"Stein, E. M. et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood 131, 387\u2013396 (2018).","journal-title":"Blood"},{"key":"2269_CR231","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2018-99-112891","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes, J. E. et al. Maturing clinical profile of IMGN779, a next-generation CD33-targeting antibody-drug conjugate, in patients with relapsed or refractory acute myeloid leukemia. Blood 132, 26 (2018).","journal-title":"Blood"},{"key":"2269_CR232","doi-asserted-by":"publisher","first-page":"7508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","volume":"38","author":"F Ravandi","year":"2020","unstructured":"Ravandi, F. et al. Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML). J. Clin. Oncol. 38, 7508\u20137508 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR233","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","volume":"123","author":"C Krupka","year":"2014","unstructured":"Krupka, C. et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell\u2013engaging antibody AMG 330. Blood 123, 356\u2013365 (2014).","journal-title":"Blood"},{"key":"2269_CR234","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2019-127977","volume":"134","author":"M Subklewe","year":"2019","unstructured":"Subklewe, M. et al. Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33\/CD3 BiTE\u00ae (bispecific T-cell engager) in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML). Blood 134, 833\u2013833 (2019).","journal-title":"Blood"},{"key":"2269_CR235","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/eji.200535628","volume":"36","author":"ASJ Marshall","year":"2006","unstructured":"Marshall, A. S. J. et al. Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation. Eur. J. Immunol. 36, 2159\u20132169 (2006).","journal-title":"Eur. J. Immunol."},{"key":"2269_CR236","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1182\/blood-2005-08-3264","volume":"107","author":"C-H Chen","year":"2006","unstructured":"Chen, C.-H. et al. Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production. Blood 107, 1459\u20131467 (2006).","journal-title":"Blood"},{"key":"2269_CR237","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/ejh.13672","volume":"107","author":"LL Ngai","year":"2021","unstructured":"Ngai, L. L. et al. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. Eur. J. Haematol. 107, 343\u2013353 (2021).","journal-title":"Eur. J. Haematol."},{"key":"2269_CR238","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3324\/haematol.2009.009811","volume":"95","author":"X Zhao","year":"2010","unstructured":"Zhao, X. et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 95, 71\u201378 (2010).","journal-title":"Haematologica"},{"key":"2269_CR239","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","volume":"64","author":"ABH Bakker","year":"2004","unstructured":"Bakker, A. B. H. et al. C-Type lectin-like molecule-1. Cancer Res. 64, 8443\u20138450 (2004).","journal-title":"Cancer Res."},{"key":"2269_CR240","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.4049\/jimmunol.1600011","volume":"197","author":"TJA Hutten","year":"2016","unstructured":"Hutten, T. J. A. et al. CLEC12A-mediated antigen uptake and cross-presentation by human dendritic cell subsets efficiently boost tumor-reactive t cell responses. J. Immunol. 197, 2715\u20132725 (2016).","journal-title":"J. Immunol."},{"key":"2269_CR241","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/cyto.b.21540","volume":"94","author":"M Toft-Petersen","year":"2018","unstructured":"Toft-Petersen, M. et al. The CLEC12A receptor marks human basophils: potential implications for minimal residual disease detection in acute myeloid leukemia. Cytom. B. Clin. Cytom. 94, 520\u2013526 (2018).","journal-title":"Cytom. B. Clin. Cytom."},{"key":"2269_CR242","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1111\/jcmm.13519","volume":"22","author":"M Bill","year":"2018","unstructured":"Bill, M. et al. Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology. J. Cell Mol. Med. 22, 2311\u20132318 (2018).","journal-title":"J. Cell Mol. Med."},{"key":"2269_CR243","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/nm.2683","volume":"18","author":"A Zloza","year":"2012","unstructured":"Zloza, A. et al. NKG2D signaling on CD8+ T cells represses T-bet and rescues CD4-unhelped CD8+ T cell memory recall but not effector responses. Nat. Med. 18, 422\u2013428 (2012).","journal-title":"Nat. Med."},{"key":"2269_CR244","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13930","volume":"8","author":"S Sheppard","year":"2017","unstructured":"Sheppard, S. et al. The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma. Nat. Commun. 8, 13930 (2017).","journal-title":"Nat. Commun."},{"key":"2269_CR245","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.285.5428.727","volume":"285","author":"S Bauer","year":"1999","unstructured":"Bauer, S. et al. Activation of NK Cells and T Cells by NKG2D, a receptor for stress-inducible MICA. Science. 285, 727\u2013729 (1999).","journal-title":"Science"},{"key":"2269_CR246","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1182\/bloodadvances.2017015230","volume":"2","author":"S Mastaglio","year":"2018","unstructured":"Mastaglio, S. et al. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. Blood Adv. 2, 335\u2013346 (2018).","journal-title":"Blood Adv."},{"key":"2269_CR247","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1182\/blood-2003-01-0019","volume":"102","author":"HR Salih","year":"2003","unstructured":"Salih, H. R. et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102, 1389\u20131396 (2003).","journal-title":"Blood"},{"key":"2269_CR248","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2004-11-4365","volume":"106","author":"T Zhang","year":"2005","unstructured":"Zhang, T., Lemoi, B. A. & Sentman, C. L. Chimeric NK-receptor\u2013bearing T cells mediate antitumor immunotherapy. Blood 106, 1544\u20131551 (2005).","journal-title":"Blood"},{"key":"2269_CR249","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/2326-6066.CIR-15-0098","volume":"3","author":"LL Lanier","year":"2015","unstructured":"Lanier, L. L. NKG2D Receptor and its ligands in host defense. Cancer Immunol. Res. 3, 575\u2013582 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"2269_CR250","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.leukres.2007.02.020","volume":"31","author":"A Rohner","year":"2007","unstructured":"Rohner, A., Langenkamp, U., Siegler, U., Kalberer, C. P. & Wodnar-Filipowicz, A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk. Res. 31, 1393\u20131402 (2007).","journal-title":"Leuk. Res."},{"key":"2269_CR251","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2007-07-101311","volume":"111","author":"S Diermayr","year":"2008","unstructured":"Diermayr, S. et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 111, 1428\u20131436 (2008).","journal-title":"Blood"},{"key":"2269_CR252","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1182\/blood.2022017935","volume":"140","author":"M Themeli","year":"2022","unstructured":"Themeli, M. Selecting CD7\u2212 T cells for CAR T-cell therapy. Blood 140, 2652\u20132653 (2022).","journal-title":"Blood"},{"key":"2269_CR253","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","volume":"31","author":"N Watanabe","year":"2023","unstructured":"Watanabe, N. et al. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol. Ther. 31, 24\u201334 (2023).","journal-title":"Mol. Ther."},{"key":"2269_CR254","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","volume":"16","author":"Y Tan","year":"2023","unstructured":"Tan, Y. et al. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J. Hematol. Oncol. 16, 34 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2269_CR255","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 32, 995\u20131007 (2022).","journal-title":"Cell Res."},{"key":"2269_CR256","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","volume":"35","author":"C Georgiadis","year":"2021","unstructured":"Georgiadis, C. et al. Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia 35, 3466\u20133481 (2021).","journal-title":"Leukemia"},{"key":"2269_CR257","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","volume":"1","author":"YT Png","year":"2017","unstructured":"Png, Y. T. et al. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 1, 2348\u20132360 (2017).","journal-title":"Blood Adv."},{"key":"2269_CR258","doi-asserted-by":"crossref","unstructured":"Lu, P. et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase i clinical trial. Blood, 140, 321\u2013334 (2022).","DOI":"10.1182\/blood.2021014498"},{"key":"2269_CR259","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva, D. et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130, 285\u2013296 (2017).","journal-title":"Blood"},{"key":"2269_CR260","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40164-022-00318-6","volume":"11","author":"X Cao","year":"2022","unstructured":"Cao, X. et al. CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed\/refractory acute myeloid leukemia. Exp. Hematol. Oncol. 11, 67 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"2269_CR261","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1182\/blood-2007-07-101600","volume":"111","author":"P Mu\u00f1oz","year":"2008","unstructured":"Mu\u00f1oz, P. et al. Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. Blood 111, 3653\u20133664 (2008).","journal-title":"Blood"},{"key":"2269_CR262","doi-asserted-by":"crossref","unstructured":"Deterre, P. et al. CD38 in T- and B-cell functions. in Human CD38 and Related Molecules 146\u2013168 (KARGER, 2000).","DOI":"10.1159\/000058767"},{"key":"2269_CR263","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/0092-8674(81)90441-4","volume":"23","author":"C Terhorst","year":"1981","unstructured":"Terhorst, C. et al. Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10. Cell 23, 771\u2013780 (1981).","journal-title":"Cell"},{"key":"2269_CR264","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0145-2126(99)00147-2","volume":"24","author":"A Keyhani","year":"2000","unstructured":"Keyhani, A. et al. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk. Res. 24, 153\u2013159 (2000).","journal-title":"Leuk. Res."},{"key":"2269_CR265","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","volume":"7","author":"T Glisovic-Aplenc","year":"2023","unstructured":"Glisovic-Aplenc, T. et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 7, 4418\u20134430 (2023).","journal-title":"Blood Adv."},{"key":"2269_CR266","doi-asserted-by":"crossref","unstructured":"Facon, T. et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 391, 1597\u20131609 (2024)","DOI":"10.1056\/NEJMoa2400712"},{"key":"2269_CR267","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal, M. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 394, 2096\u20132107 (2019).","journal-title":"Lancet"},{"key":"2269_CR268","doi-asserted-by":"publisher","first-page":"e121813e","DOI":"10.1097\/01.HS9.0000968912.12181.3e","volume":"7","author":"A Baruchel","year":"2023","unstructured":"Baruchel, A. et al. P501: Isatuximab plus chemotherapy for pediatric relapsed\/refractory acute lymphoblastic leukemia or acute myeloid leukemia (isakids): interim efficacy analysis. Hemasphere 7, e121813e (2023).","journal-title":"Hemasphere"},{"key":"2269_CR269","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","volume":"104","author":"J Naik","year":"2019","unstructured":"Naik, J. et al. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica 104, e100\u2013e103 (2019).","journal-title":"Haematologica"},{"key":"2269_CR270","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/sj.leu.2402336","volume":"16","author":"M Van Driel","year":"2002","unstructured":"Van Driel, M. et al. CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells. Leukemia 16, 135\u2013143 (2002).","journal-title":"Leukemia"},{"key":"2269_CR271","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00262-003-0494-4","volume":"53","author":"K-H Heider","year":"2004","unstructured":"Heider, K.-H., Kuthan, H., Stehle, G. & Munzert, G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol. Immunother. 53, 567\u2013579 (2004).","journal-title":"Cancer Immunol. Immunother."},{"key":"2269_CR272","doi-asserted-by":"crossref","unstructured":"Wang, Z., Zhao, K., Hackert, T. & Z\u00f6ller, M. CD44\/CD44v6 a reliable companion in cancer-initiating cell maintenance and tumor progression. Front. Cell Dev. Biol. 6, (2018).","DOI":"10.3389\/fcell.2018.00097"},{"key":"2269_CR273","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","volume":"122","author":"M Casucci","year":"2013","unstructured":"Casucci, M. et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122, 3461\u20133472 (2013).","journal-title":"Blood"},{"key":"2269_CR274","doi-asserted-by":"crossref","unstructured":"Tang, L. et al. CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations. Clin. Transl. Med. 12, e1007 (2022).","DOI":"10.1002\/ctm2.1043"},{"key":"2269_CR275","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1089\/hum.2020.216","volume":"32","author":"A Stornaiuolo","year":"2021","unstructured":"Stornaiuolo, A. et al. Characterization and functional analysis of cd44v6.car t cells endowed with a new low-affinity nerve growth factor receptor-based spacer. Hum. Gene Ther. 32, 744\u2013760 (2021).","journal-title":"Hum. Gene Ther."},{"key":"2269_CR276","doi-asserted-by":"crossref","unstructured":"Wu, G. et al. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. Front. Immunol. 14, 1093750 (2023).","DOI":"10.3389\/fimmu.2023.1093750"},{"key":"2269_CR277","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.2020008221","volume":"138","author":"T Sauer","year":"2021","unstructured":"Sauer, T. et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood 138, 318\u2013330 (2021).","journal-title":"Blood"},{"key":"2269_CR278","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","volume":"26","author":"C Riether","year":"2020","unstructured":"Riether, C. et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat. Med. 26, 1459\u20131467 (2020).","journal-title":"Nat. Med."},{"key":"2269_CR279","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.xcrm.2022.100639","volume":"3","author":"J Mirazee","year":"2022","unstructured":"Mirazee, J. & Shah, N. N. CD70 CAR T cells in AML: form follows function. Cell Rep. Med. 3, 100639 (2022).","journal-title":"Cell Rep. Med."},{"key":"2269_CR280","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver, N., Schlenk, R. F., Russell, N. H. & Levis, M. J. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33, 299\u2013312 (2019).","journal-title":"Leukemia"},{"key":"2269_CR281","doi-asserted-by":"publisher","first-page":"204062071982731","DOI":"10.1177\/2040620719827310","volume":"10","author":"NJ Short","year":"2019","unstructured":"Short, N. J., Kantarjian, H., Ravandi, F. & Daver, N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther. Adv. Hematol. 10, 204062071982731 (2019).","journal-title":"Ther. Adv. Hematol."},{"key":"2269_CR282","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba, H. P. et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1571\u20131583 (2023).","journal-title":"Lancet"},{"key":"2269_CR283","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1200\/JCO.23.01061","volume":"42","author":"ES Wang","year":"2024","unstructured":"Wang, E. S. et al. Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML. J. Clin. Oncol. 42, 1776\u20131787 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR284","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1182\/blood.2023020301","volume":"142","author":"S Loo","year":"2023","unstructured":"Loo, S. et al. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG. Blood 142, 1960\u20131971 (2023).","journal-title":"Blood"},{"key":"2269_CR285","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1182\/blood.V128.22.1072.1072","volume":"128","author":"CD Chien","year":"2016","unstructured":"Chien, C. D. et al. Preclinical development of FLT3-Redirected chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia. Blood 128, 1072 (2016).","journal-title":"Blood"},{"key":"2269_CR286","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","volume":"32","author":"H Jetani","year":"2018","unstructured":"Jetani, H. et al. CAR T-cells targeting FLT3 have potent activity against FLT3\u2212ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia 32, 1168\u20131179 (2018).","journal-title":"Leukemia"},{"key":"2269_CR287","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2021-151196","volume":"138","author":"S Sleiman","year":"2021","unstructured":"Sleiman, S. et al. Anti-FLT3 CAR T cells in acute myeloid leukemia. Blood 138, 1703 (2021).","journal-title":"Blood"},{"key":"2269_CR288","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","volume":"28","author":"C Sommer","year":"2020","unstructured":"Sommer, C. et al. Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery. Mol. Ther. 28, 2237\u20132251 (2020).","journal-title":"Mol. Ther."},{"key":"2269_CR289","doi-asserted-by":"crossref","unstructured":"Barneh, F. et al. Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia. Haematologica 109, 4131\u20134136 (2024)","DOI":"10.3324\/haematol.2024.285707"},{"key":"2269_CR290","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","volume":"32","author":"F Perna","year":"2017","unstructured":"Perna, F. et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 32, 506\u2013519.e5 (2017).","journal-title":"Cancer Cell"},{"key":"2269_CR291","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cyto.b.21050","volume":"84B","author":"H Dobrowolska","year":"2013","unstructured":"Dobrowolska, H. et al. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytom. B. Clin. Cytom. 84B, 21\u201329 (2013).","journal-title":"Cytom. B. Clin. Cytom."},{"key":"2269_CR292","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","volume":"17","author":"S Loff","year":"2020","unstructured":"Loff, S. et al. Rapidly switchable universal car-t cells for treatment of CD123-positive leukemia. Mol. Ther. Oncol.17, 408\u2013420 (2020).","journal-title":"Mol. Ther. Oncol."},{"key":"2269_CR293","doi-asserted-by":"publisher","first-page":"e458","DOI":"10.1038\/bcj.2016.61","volume":"6","author":"M Cartellieri","year":"2016","unstructured":"Cartellieri, M. et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 6, e458\u2013e458 (2016).","journal-title":"Blood Cancer J."},{"key":"2269_CR294","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.imlet.2019.05.003","volume":"211","author":"M Bachmann","year":"2019","unstructured":"Bachmann, M. The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells. Immunol. Lett. 211, 13\u201322 (2019).","journal-title":"Immunol. Lett."},{"key":"2269_CR295","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1182\/blood-2023-177867","volume":"142","author":"M Wermke","year":"2023","unstructured":"Wermke, M. et al. Updated results from a phase i dose escalation study of the rapidly-switchable universal CAR-T Therapy UniCAR-T-CD123 in relapsed\/refractory AML. Blood 142, 3465 (2023).","journal-title":"Blood"},{"key":"2269_CR296","unstructured":"ClinicalTrials.gov. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05949125."},{"key":"2269_CR297","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29668-9","volume":"13","author":"M Sugita","year":"2022","unstructured":"Sugita, M. et al. Allogeneic TCR\u03b1\u03b2 deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nat. Commun. 13, 2227 (2022).","journal-title":"Nat. Commun."},{"key":"2269_CR298","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29669-8","volume":"13","author":"T Cai","year":"2022","unstructured":"Cai, T. et al. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat. Commun. 13, 2228 (2022).","journal-title":"Nat. Commun."},{"key":"2269_CR299","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106928","volume":"121","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju, N. et al. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): clinicopathological insights. Leuk. Res. 121, 106928 (2022).","journal-title":"Leuk. Res."},{"key":"2269_CR300","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1182\/blood-2022-169928","volume":"140","author":"DA Sallman","year":"2022","unstructured":"Sallman, D. A. et al. Ameli-01: A phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD123+ acute myeloid leukemia (AML). Blood 140, 2371\u20132373 (2022).","journal-title":"Blood"},{"key":"2269_CR301","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1182\/blood-2022-170201","volume":"140","author":"S Naik","year":"2022","unstructured":"Naik, S. et al. Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial. Blood 140, 4584\u20134585 (2022).","journal-title":"Blood"},{"key":"2269_CR302","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1158\/1538-7445.AM2022-587","volume":"82","author":"JP Edwards","year":"2022","unstructured":"Edwards, J. P. et al. Abstract 587: ACLX-002, a novel CD123-targeted universal CAR-T cell therapy for relapsed or refractory acute myeloid leukemia that can be activated and silenced in vivo with soluble protein adapters in a dose dependent manner. Cancer Res. 82, 587 (2022).","journal-title":"Cancer Res."},{"key":"2269_CR303","first-page":"1359","volume":"130","author":"KD Cummins","year":"2017","unstructured":"Cummins, K. D. et al. Treating relapsed \/ refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells. Blood 130, 1359 (2017).","journal-title":"Blood"},{"key":"2269_CR304","doi-asserted-by":"publisher","first-page":"PR14","DOI":"10.1158\/2326-6074.TUMIMM18-PR14","volume":"8","author":"LE Budde","year":"2020","unstructured":"Budde, L. E. et al. Abstract PR14: CD123CAR displays clinical activity in relapsed\/refractory (R\/R) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): Safety and efficacy results from a phase 1 study. Cancer Immunol. Res. 8, PR14\u2013PR14 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"2269_CR305","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","volume":"130","author":"L Budde","year":"2017","unstructured":"Budde, L. et al. Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial. Blood 130, 811\u2013811 (2017).","journal-title":"Blood"},{"key":"2269_CR306","doi-asserted-by":"publisher","first-page":"e003149","DOI":"10.1136\/jitc-2021-003149","volume":"9","author":"H Qin","year":"2021","unstructured":"Qin, H. et al. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. J. Immunother. Cancer 9, e003149 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2269_CR307","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1080\/10428194.2017.1421756","volume":"59","author":"JK Lamba","year":"2018","unstructured":"Lamba, J. K. et al. CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients. Leuk. Lymphoma 59, 2250\u20132253 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"2269_CR308","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1158\/1078-0432.CCR-12-3115","volume":"19","author":"L Mortland","year":"2013","unstructured":"Mortland, L. et al. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin\u2013containing chemotherapy. Clin. Cancer Res. 19, 1620\u20131627 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2269_CR309","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/s41375-020-0755-7","volume":"34","author":"CD Godwin","year":"2020","unstructured":"Godwin, C. D. et al. The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia. Leukemia 34, 2479\u20132483 (2020).","journal-title":"Leukemia"},{"key":"2269_CR310","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2023-179667","volume":"142","author":"NN Shah","year":"2023","unstructured":"Shah, N. N. et al. CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial. Blood 142, 771\u2013771 (2023).","journal-title":"Blood"},{"key":"2269_CR311","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1016\/j.jtct.2023.12.195","volume":"30","author":"B Bowser","year":"2024","unstructured":"Bowser, B. et al. Success of centralized manufacturing of CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML. Transplant. Cell. Ther. 30, S153\u2013S154 (2024).","journal-title":"Transplant. Cell. Ther."},{"key":"2269_CR312","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro, F. P. et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia 35, 3282\u20133286 (2021).","journal-title":"Leukemia"},{"key":"2269_CR313","doi-asserted-by":"publisher","first-page":"10313","DOI":"10.1182\/blood-2022-169142","volume":"140","author":"DA Sallman","year":"2022","unstructured":"Sallman, D. A. et al. Phase 1\/1b safety study of prgn-3006 ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes. Blood 140, 10313\u201310315 (2022).","journal-title":"Blood"},{"key":"2269_CR314","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1200\/JCO.2024.42.16_suppl.6518","volume":"42","author":"J Pan","year":"2024","unstructured":"Pan, J. et al. Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia. J. Clin. Oncol. 42, 6518\u20136518 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR315","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1182\/blood-2023-180990","volume":"142","author":"NN Shah","year":"2023","unstructured":"Shah, N. N. et al. Phase 1\/2 Study of donor-derived anti-CD33 chimeric antigen receptor expressing T cells (VCAR33) in patients with relapsed or refractory acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Blood 142, 4862 (2023).","journal-title":"Blood"},{"key":"2269_CR316","doi-asserted-by":"crossref","unstructured":"Appelbaum, J. et al. Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing. J. Clin. Investig. 134, e169155 (2024).","DOI":"10.1172\/JCI162593"},{"key":"2269_CR317","doi-asserted-by":"crossref","unstructured":"Liu, J. et al. Targeted CD7 CAR T-cells for treatment of T-lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances. Front. Immunol. 14, 1108959 (2023).","DOI":"10.3389\/fimmu.2023.1170968"},{"key":"2269_CR318","doi-asserted-by":"crossref","unstructured":"O'Hear C, et al. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica 100, 336\u2013344 (2015).","DOI":"10.3324\/haematol.2014.112748"},{"key":"2269_CR319","unstructured":"Ma, Y.-J. et al. CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment. Am. J. Cancer Res. 12, 1454\u20131463 (2022)."},{"key":"2269_CR320","doi-asserted-by":"publisher","first-page":"TPS720","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS720","volume":"42","author":"ZA Wainberg","year":"2024","unstructured":"Wainberg, Z. A. et al. AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma. J. Clin. Oncol. 42, TPS720\u2013TPS720 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR321","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin, X. et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J. Hematol. Oncol. 15, 88 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2269_CR322","doi-asserted-by":"publisher","first-page":"6323","DOI":"10.1158\/1538-7445.AM2024-6323","volume":"84","author":"B Francica","year":"2024","unstructured":"Francica, B. et al. Abstract 6323: Preclinical evaluation of CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, that exhibits specific and potent toxicity in acute myeloid leukemia (AML) xenograft models. Cancer Res. 84, 6323\u20136323 (2024).","journal-title":"Cancer Res."},{"key":"2269_CR323","doi-asserted-by":"crossref","unstructured":"Cui, Q. et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J. Hematol. Oncol. 14, 153 (2021).","DOI":"10.1186\/s13045-021-01092-4"},{"key":"2269_CR324","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu, Y. et al. Sequential CD7 CAR T-Cell therapy and allogeneic HSCT without GVHD prophylaxis. N. Engl. J. Med. 390, 1467\u20131480 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR325","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","volume":"28","author":"M Zhang","year":"2022","unstructured":"Zhang, M. et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma. Clin. Cancer Res. 28, 2830\u20132843 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2269_CR326","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister, S. H. et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma. Cancer Immunol. Res. 7, 100\u2013112 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2269_CR327","doi-asserted-by":"publisher","first-page":"TPS3102","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS3102","volume":"34","author":"S Nikiforow","year":"2016","unstructured":"Nikiforow, S. et al. A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML\/MDS and multiple myeloma. J. Clin. Oncol. 34, TPS3102\u2013TPS3102 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR328","unstructured":"Liu, F. et al. First-in-human CLL1-CD33 compound CAR (cCAR) T cell therapy in relapsed and refractory acute myeloid leukemia. EHA Library Abstract S149 (2020)."},{"key":"2269_CR329","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4, 92\u2013101 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2269_CR330","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/ijc.32201","volume":"145","author":"S Stock","year":"2019","unstructured":"Stock, S. et al. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. Int. J. Cancer 145, 1312\u20131324 (2019).","journal-title":"Int. J. Cancer"},{"key":"2269_CR331","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s00262-013-1459-x","volume":"62","author":"A Casati","year":"2013","unstructured":"Casati, A. et al. Clinical-scale selection and viral transduction of human na\u00efve and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol. Immunother. 62, 1563\u20131573 (2013).","journal-title":"Cancer Immunol. Immunother."},{"key":"2269_CR332","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/CJI.0b013e318270dec7","volume":"35","author":"X Wang","year":"2012","unstructured":"Wang, X. et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory t cells manufactured at clinical scale. J. Immunother. 35, 689\u2013701 (2012).","journal-title":"J. Immunother."},{"key":"2269_CR333","first-page":"348","volume":"199","author":"M Schmueck-Henneresse","year":"2017","unstructured":"Schmueck-Henneresse, M. et al. Comprehensive approach for identifying the T cell subset origin of CD3 and CD28 antibody\u2013activated chimeric antigen receptor-modified T cells. J. Immunother. 199, 348\u2013362 (2017).","journal-title":"J. Immunother."},{"key":"2269_CR334","doi-asserted-by":"crossref","unstructured":"Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C. & Chen, Y. Y. CAR-T cell manufacturing: major process parameters and next-generation strategies. J. Exp. Med. 221, e20230903 (2024).","DOI":"10.1084\/jem.20230903"},{"key":"2269_CR335","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","volume":"559","author":"TL Roth","year":"2018","unstructured":"Roth, T. L. et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559, 405\u2013409 (2018).","journal-title":"Nature"},{"key":"2269_CR336","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. \u201cOff-the-shelf\u201dallogeneic CAR T cells: development and challenges. Nat. Rev. Drug. Discov. 19, 185\u2013199 (2020).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"2269_CR337","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","volume":"75","author":"L Poirot","year":"2015","unstructured":"Poirot, L. et al. Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies. Cancer Res. 75, 3853\u20133864 (2015).","journal-title":"Cancer Res."},{"key":"2269_CR338","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/cancers14051241","volume":"14","author":"P Vishwasrao","year":"2022","unstructured":"Vishwasrao, P., Li, G., Boucher, J. C., Smith, D. L. & Hui, S. K. Emerging CAR T cell strategies for the treatment of AML. Cancers 14, 1241 (2022).","journal-title":"Cancers"},{"key":"2269_CR339","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"2269_CR340","doi-asserted-by":"crossref","unstructured":"Watanabe, K., Kuramitsu, S., Posey, A. D. & June, C. H. Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology. Front. Immunol. 9 2486 (2018).","DOI":"10.3389\/fimmu.2018.02486"},{"key":"2269_CR341","doi-asserted-by":"crossref","unstructured":"Mao, R., Kong, W. & He, Y. The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: moderate is better. Front. Immunol. 13, 900241 (2022).","DOI":"10.3389\/fimmu.2022.1032403"},{"key":"2269_CR342","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","volume":"28","author":"J Mansilla-Soto","year":"2022","unstructured":"Mansilla-Soto, J. et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat. Med. 28, 345\u2013352 (2022).","journal-title":"Nat. Med."},{"key":"2269_CR343","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"2269_CR344","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"2269_CR345","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25605-4","volume":"12","author":"MS Hwang","year":"2021","unstructured":"Hwang, M. S. et al. Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. Nat. Commun. 12, 5271 (2021).","journal-title":"Nat. Commun."},{"key":"2269_CR346","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41587-019-0329-2","volume":"38","author":"M MacKay","year":"2020","unstructured":"MacKay, M. et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat. Biotechnol. 38, 233\u2013244 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2269_CR347","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh, M., Mansilla-Soto, J., Rivi\u00e8re, I. & Sadelain, M. Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov. 13, 829\u2013843 (2023).","journal-title":"Cancer Discov."},{"key":"2269_CR348","doi-asserted-by":"crossref","unstructured":"Mog, B. J. et al. Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities. Sci. Transl. Med. 16, eadh1696 (2024).","DOI":"10.1126\/scitranslmed.adg7123"},{"key":"2269_CR349","doi-asserted-by":"crossref","unstructured":"Liu, Y. et al. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci. Transl. Med. 13, eabd8636 (2021).","DOI":"10.1126\/scitranslmed.abb5191"},{"key":"2269_CR350","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10097-0","volume":"10","author":"PA Baeuerle","year":"2019","unstructured":"Baeuerle, P. A. et al. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat. Commun. 10, 2087 (2019).","journal-title":"Nat. Commun."},{"key":"2269_CR351","doi-asserted-by":"publisher","unstructured":"Yu, L. et al. Converting TCR-based chimeric antigen receptor STAR into dual-specific targeting receptor for cancer immunotherapy. Mol. Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.001 (2025).","DOI":"10.1016\/j.ymthe.2025.02.001"},{"key":"2269_CR352","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114949","volume":"43","author":"D Huang","year":"2024","unstructured":"Huang, D. et al. TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens. Cell Rep. 43, 114949 (2024).","journal-title":"Cell Rep."},{"key":"2269_CR353","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62\u201368 (2015).","journal-title":"Science"},{"key":"2269_CR354","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","volume":"181","author":"EW Weber","year":"2020","unstructured":"Weber, E. W., Maus, M. V. & Mackall, C. L. The emerging landscape of immune cell therapies. Cell 181, 46\u201362 (2020).","journal-title":"Cell"},{"key":"2269_CR355","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","volume":"609","author":"J Carnevale","year":"2022","unstructured":"Carnevale, J. et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 609, 174\u2013182 (2022).","journal-title":"Nature"},{"key":"2269_CR356","doi-asserted-by":"publisher","first-page":"11978","DOI":"10.1073\/pnas.1819992116","volume":"116","author":"F Borot","year":"2019","unstructured":"Borot, F. et al. Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proc. Natl. Acad. Sci. USA 116, 11978\u201311987 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2269_CR357","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439\u20131453.e19 (2018).","journal-title":"Cell"},{"key":"2269_CR358","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ijc.33865","volume":"150","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int. J. Cancer 150, 1141\u20131155 (2022).","journal-title":"Int. J. Cancer"},{"key":"2269_CR359","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","volume":"621","author":"G Casirati","year":"2023","unstructured":"Casirati, G. et al. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. Nature 621, 404\u2013414 (2023).","journal-title":"Nature"},{"key":"2269_CR360","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.stem.2024.09.003","volume":"31","author":"R-J Ji","year":"2024","unstructured":"Ji, R.-J. et al. Epitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia. Cell Stem Cell 31, 1650\u20131666.e8 (2024).","journal-title":"Cell Stem Cell"},{"key":"2269_CR361","doi-asserted-by":"crossref","unstructured":"Wellhausen, N. et al. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci. Transl. Med. 15, eabm2443 (2023).","DOI":"10.1126\/scitranslmed.adi1145"},{"key":"2269_CR362","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-019-0763-0","volume":"12","author":"D Liu","year":"2019","unstructured":"Liu, D., Zhao, J. & Song, Y. Engineering switchable and programmable universal CARs for CAR T therapy. J. Hematol. Oncol. 12, 69 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2269_CR363","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112797","volume":"42","author":"Y Cui","year":"2023","unstructured":"Cui, Y. et al. T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity. Cell Rep. 42, 112797 (2023).","journal-title":"Cell Rep."},{"key":"2269_CR364","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/cancers15112944","volume":"15","author":"J Zarychta","year":"2023","unstructured":"Zarychta, J., Kowalczyk, A., Krawczyk, M., Lejman, M. & Zawitkowska, J. CAR-T cells immunotherapies for the treatment of acute myeloid leukemia-recent advances. Cancers 15, 2944 (2023).","journal-title":"Cancers"},{"key":"2269_CR365","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21078-7","volume":"12","author":"JH Cho","year":"2021","unstructured":"Cho, J. H. et al. Engineering advanced logic and distributed computing in human CAR immune cells. Nat. Commun. 12, 792 (2021).","journal-title":"Nat. Commun."},{"key":"2269_CR366","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.3390\/cancers13194785","volume":"13","author":"E Kittel-Boselli","year":"2021","unstructured":"Kittel-Boselli, E. et al. Targeting acute myeloid leukemia using the revCAR platform: a programmable, switchable and combinatorial strategy. Cancers 13, 4785 (2021).","journal-title":"Cancers"},{"key":"2269_CR367","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1126\/science.aba6527","volume":"369","author":"MJ Lajoie","year":"2020","unstructured":"Lajoie, M. J. et al. Designed protein logic to target cells with precise combinations of surface antigens. Science 369, 1637\u20131643 (2020).","journal-title":"Science"},{"key":"2269_CR368","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164, 770\u2013779 (2016).","journal-title":"Cell"},{"key":"2269_CR369","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley, A. M. et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615, 507\u2013516 (2023).","journal-title":"Nature"},{"key":"2269_CR370","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426\u20131438.e11 (2018).","journal-title":"Cell"},{"key":"2269_CR371","doi-asserted-by":"crossref","unstructured":"Allen, G. M. et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science 378 (2022).","DOI":"10.1126\/science.aba1624"},{"key":"2269_CR372","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.cell.2022.03.023","volume":"185","author":"I Zhu","year":"2022","unstructured":"Zhu, I. et al. Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell 185, 1431\u20131443.e16 (2022).","journal-title":"Cell"},{"key":"2269_CR373","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167, 419\u2013432.e16 (2016).","journal-title":"Cell"},{"key":"2269_CR374","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","volume":"164","author":"L Morsut","year":"2016","unstructured":"Morsut, L. et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell 164, 780\u2013791 (2016).","journal-title":"Cell"},{"key":"2269_CR375","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","volume":"2","author":"RM Richards","year":"2021","unstructured":"Richards, R. M. et al. NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity. Blood Cancer Discov. 2, 648\u2013665 (2021).","journal-title":"Blood Cancer Discov."},{"key":"2269_CR376","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2021.09.003","volume":"74","author":"S Simon","year":"2022","unstructured":"Simon, S., Bugos, G., Salter, A. I. & Riddell, S. R. Synthetic receptors for logic gated T cell recognition and function. Curr. Opin. Immunol. 74, 9\u201317 (2022).","journal-title":"Curr. Opin. Immunol."},{"key":"2269_CR377","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","volume":"4","author":"E Zah","year":"2016","unstructured":"Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C. & Chen, Y. Y. T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol. Res. 4, 498\u2013508 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"2269_CR378","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.32","volume":"2","author":"Z Grada","year":"2013","unstructured":"Grada, Z. et al. TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic Acids 2, e105 (2013).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2269_CR379","doi-asserted-by":"crossref","unstructured":"Wang, J.-Y. & Wang, L. CAR T cell therapy: where are we now, and where are we heading? Blood sci. 5, 237\u2013248 (2023).","DOI":"10.1097\/BS9.0000000000000173"},{"key":"2269_CR380","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2643-3230.BCD-23-0020","volume":"4","author":"A Nelde","year":"2023","unstructured":"Nelde, A. et al. Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells. Blood Cancer Discov. 4, 468\u2013489 (2023).","journal-title":"Blood Cancer Discov."},{"key":"2269_CR381","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1182\/blood-2014-11-612721","volume":"125","author":"RC Lynn","year":"2015","unstructured":"Lynn, R. C. et al. Targeting of folate receptor \u03b2 on acute myeloid leukemia blasts with chimeric antigen receptor\u2013expressing T cells. Blood 125, 3466\u20133476 (2015).","journal-title":"Blood"},{"key":"2269_CR382","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1002\/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S","volume":"73","author":"JF Ross","year":"1994","unstructured":"Ross, J. F., Chaudhuri, P. K. & Ratnam, M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73, 2432\u20132443 (1994).","journal-title":"Cancer"},{"key":"2269_CR383","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1182\/blood.V96.10.3529","volume":"96","author":"H Wang","year":"2000","unstructured":"Wang, H., Zheng, X., Behm, F. G. & Ratnam, M. Differentiation-independent retinoid induction of folate receptor type \u03b2, a potential tumor target in myeloid leukemia. Blood 96, 3529\u20133536 (2000).","journal-title":"Blood"},{"key":"2269_CR384","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/leu.2016.373","volume":"31","author":"S Rafiq","year":"2017","unstructured":"Rafiq, S. et al. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia 31, 1788\u20131797 (2017).","journal-title":"Leukemia"},{"key":"2269_CR385","doi-asserted-by":"crossref","unstructured":"Di Stasi, A., Jimenez, A. M., Minagawa, K., Al-Obaidi, M. & Rezvani, K. Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front. Immunol. 6, 236 (2015).","DOI":"10.3389\/fimmu.2015.00036"},{"key":"2269_CR386","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41423-019-0321-2","volume":"17","author":"Z Li","year":"2020","unstructured":"Li, Z. et al. LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol. Immunol. 17, 272\u2013282 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"2269_CR387","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","volume":"562","author":"M Deng","year":"2018","unstructured":"Deng, M. et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature 562, 605\u2013609 (2018).","journal-title":"Nature"},{"key":"2269_CR388","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/BS9.0000000000000109","volume":"4","author":"T Yang","year":"2022","unstructured":"Yang, T. et al. LILRB4, an immune checkpoint on myeloid cells. Blood Sci. 4, 49\u201356 (2022).","journal-title":"Blood Sci."},{"key":"2269_CR389","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","volume":"26","author":"S John","year":"2018","unstructured":"John, S. et al. A novel anti-LILRB4 CAR-T Cell for the treatment of monocytic AML. Mol. Ther. 26, 2487\u20132495 (2018).","journal-title":"Mol. Ther."},{"key":"2269_CR390","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/15384101.2015.1121324","volume":"15","author":"X Kang","year":"2016","unstructured":"Kang, X. et al. Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors. Cell Cycle 15, 25\u201340 (2016).","journal-title":"Cell Cycle"},{"key":"2269_CR391","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1182\/blood-2024-207297","volume":"144","author":"X Zhao","year":"2024","unstructured":"Zhao, X. et al. LILRB4 synthetic T-cell receptor and antigen receptor-T (STAR-T) for refractory\/relapsed acute myeloid leukemia: first-in-human phase I clinical trial. Blood 144, 4831\u20134831 (2024).","journal-title":"Blood"},{"key":"2269_CR392","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1182\/blood-2024-206538","volume":"144","author":"GN Mannis","year":"2024","unstructured":"Mannis, G. N. et al. IO-202, a Novel Anti-LILRB4 antibody, with azacitidine for hypomethylating agent-naive chronic myelomonocytic leukemia: phase 1b expansion cohort results. Blood 144, 1008\u20131008 (2024).","journal-title":"Blood"},{"key":"2269_CR393","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49466-9","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang, Y., Quan, Y., He, J., Chen, S. & Dong, Z. SLAM-family receptors promote resolution of ILC2-mediated inflammation. Nat. Commun. 15, 5056 (2024).","journal-title":"Nat. Commun."},{"key":"2269_CR394","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22230-z","volume":"12","author":"L Radomir","year":"2021","unstructured":"Radomir, L. et al. The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5. Nat. Commun. 12, 1893 (2021).","journal-title":"Nat. Commun."},{"key":"2269_CR395","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.1182\/blood-2022-165339","volume":"140","author":"L P\u00e9rez-Amill","year":"2022","unstructured":"P\u00e9rez-Amill, L. et al. CD84: a novel target for CAR T-cell therapy for acute myeloid leukemia. Blood 140, 7379\u20137381 (2022).","journal-title":"Blood"},{"key":"2269_CR396","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1182\/blood.2021013184","volume":"138","author":"S Ghorashian","year":"2021","unstructured":"Ghorashian, S. & Pule, M. Siglec-6 CAR T: magic bullet for a moving target. Blood 138, 1786\u20131787 (2021).","journal-title":"Blood"},{"key":"2269_CR397","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood.2020009192","volume":"138","author":"H Jetani","year":"2021","unstructured":"Jetani, H. et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood 138, 1830\u20131842 (2021).","journal-title":"Blood"},{"key":"2269_CR398","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03153-9","volume":"23","author":"P Klaihmon","year":"2023","unstructured":"Klaihmon, P., Luanpitpong, S., Kang, X. & Issaragrisil, S. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells. Cancer Cell. Int. 23, 297 (2023).","journal-title":"Cancer Cell. Int."},{"key":"2269_CR399","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf, Y., Anderson, A. C. & Kuchroo, V. K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 20, 173\u2013185 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2269_CR400","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/ni988","volume":"4","author":"CA Sabatos","year":"2003","unstructured":"Sabatos, C. A. et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat. Immunol. 4, 1102\u20131110 (2003).","journal-title":"Nat. Immunol."},{"key":"2269_CR401","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s43018-023-00652-6","volume":"4","author":"K Mandal","year":"2023","unstructured":"Mandal, K. et al. Structural surfaceomics reveals an AML-specific conformation of integrin \u03b22 as a CAR T cellular therapy target. Nat. Cancer 4, 1592\u20131609 (2023).","journal-title":"Nat. Cancer"},{"key":"2269_CR402","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.it.2019.01.008","volume":"40","author":"B Blanco","year":"2019","unstructured":"Blanco, B., Compte, M., Lykkemark, S., Sanz, L. & Alvarez-Vallina, L. T Cell-redirecting strategies to \u2018STAb\u2019 tumors: beyond CARs and bispecific antibodies. Trends Immunol. 40, 243\u2013257 (2019).","journal-title":"Trends Immunol."},{"key":"2269_CR403","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls, A. M., Coupet, T. A. & Sentman, C. L. Bispecific T-cell engagers for cancer immunotherapy. Immunol. Cell Biol. 93, 290\u2013296 (2015).","journal-title":"Immunol. Cell Biol."},{"key":"2269_CR404","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991\u2013998 (2002).","journal-title":"Nat. Immunol."},{"key":"2269_CR405","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1038\/bcj.2016.38","volume":"6","author":"X Liu","year":"2016","unstructured":"Liu, X. et al. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J. 6, e430\u2013e430 (2016).","journal-title":"Blood Cancer J."},{"key":"2269_CR406","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Reinoso, A. et al. Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers. J. Immunother. Cancer 10, e004042 (2022).","DOI":"10.1136\/jitc-2022-005333"},{"key":"2269_CR407","doi-asserted-by":"publisher","first-page":"2444701","DOI":"10.1080\/2162402X.2024.2444701","volume":"14","author":"M Velasco-Sidro","year":"2025","unstructured":"Velasco-Sidro, M., Arroyo-R\u00f3denas, J., D\u00edez-Alonso, L., Ram\u00edrez-Fern\u00e1ndez, \u00c1 & \u00c1lvarez-Vallina, L. Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers. Oncoimmunology 14, 2444701 (2025).","journal-title":"Oncoimmunology"},{"key":"2269_CR408","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1200\/JCO.2024.42.16_suppl.2550","volume":"42","author":"J Arroyo-Rodenas","year":"2024","unstructured":"Arroyo-Rodenas, J. et al. Effect of CD22-directed CAR-T cells secreting anti-CD19 T cell engagers on control of leukemia progression compared to tandem anti-CD19\/CD22 CAR-T cells. J. Clin. Oncol. 42, 2550\u20132550 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR409","doi-asserted-by":"crossref","unstructured":"Silva, H. et al. CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML. Blood 720\u2013731 (2024).","DOI":"10.1182\/blood.2023023210"},{"key":"2269_CR410","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s13402-024-00971-5","volume":"47","author":"Z Yan","year":"2024","unstructured":"Yan, Z. et al. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells. Cell Oncol. 47, 1879\u20131895 (2024).","journal-title":"Cell Oncol."},{"key":"2269_CR411","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","volume":"19","author":"B Silva-Santos","year":"2019","unstructured":"Silva-Santos, B., Mensurado, S. & Coffelt, S. B. \u03b3\u03b4 T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat. Rev. Cancer 19, 392\u2013404 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"2269_CR412","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41586-024-07439-4","volume":"630","author":"W Xin","year":"2024","unstructured":"Xin, W. et al. Structures of human \u03b3\u03b4 T cell receptor\u2013CD3 complex. Nature 630, 222\u2013229 (2024).","journal-title":"Nature"},{"key":"2269_CR413","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun, L., Su, Y., Jiao, A., Wang, X. & Zhang, B. T cells in health and disease. Signal Transduct. Target Ther. 8, 235 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2269_CR414","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41577-020-00452-4","volume":"21","author":"JC Ribot","year":"2021","unstructured":"Ribot, J. C., Lopes, N. & Silva-Santos, B. \u03b3\u03b4 T cells in tissue physiology and surveillance. Nat. Rev. Immunol. 21, 221\u2013232 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"2269_CR415","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","volume":"20","author":"S Mensurado","year":"2023","unstructured":"Mensurado, S., Blanco-Dom\u00ednguez, R. & Silva-Santos, B. The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178\u2013191 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2269_CR416","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1182\/blood.2023022992","volume":"143","author":"S Mensurado","year":"2024","unstructured":"Mensurado, S. et al. CD155\/PVR determines acute myeloid leukemia targeting by Delta One T cells. Blood 143, 1488\u20131495 (2024).","journal-title":"Blood"},{"key":"2269_CR417","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2326-6066.CIR-18-0647","volume":"7","author":"B Di Lorenzo","year":"2019","unstructured":"Di Lorenzo, B. et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells. Cancer Immunol. Res. 7, 552\u2013558 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2269_CR418","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia, F., Perego, M. & Gabrilovich, D. Myeloid-derived suppressor cells coming of age. Nat. Immunol. 19, 108\u2013119 (2018).","journal-title":"Nat. Immunol."},{"key":"2269_CR419","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li, K. et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct. Target Ther. 6, 362 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2269_CR420","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J. & Umansky, V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat. Rev. Clin. Oncol. 21, 147\u2013164 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2269_CR421","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).","journal-title":"Nat. Commun."},{"key":"2269_CR422","doi-asserted-by":"crossref","unstructured":"Di, S. et al. Combined adjuvant of Poly I:C improves antitumor effects of CAR-T cells. Front. Oncol. 9, 1208 (2019).","DOI":"10.3389\/fonc.2019.00241"},{"key":"2269_CR423","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"2269_CR424","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1158\/0008-5472.CAN-10-3843","volume":"71","author":"H Singh","year":"2011","unstructured":"Singh, H. et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 71, 3516\u20133527 (2011).","journal-title":"Cancer Res."},{"key":"2269_CR425","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1182\/blood.V128.22.816.816","volume":"128","author":"MP Avanzi","year":"2016","unstructured":"Avanzi, M. P. et al. IL-18 secreting CAR T cells enhance cell persistence, induce prolonged B cell aplasia and eradicate CD19+ tumor cells without need for prior conditioning. Blood 128, 816 (2016).","journal-title":"Blood"},{"key":"2269_CR426","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1126\/science.aar3246","volume":"359","author":"JT Sockolosky","year":"2018","unstructured":"Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science 359, 1037\u20131042 (2018).","journal-title":"Science"},{"key":"2269_CR427","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).","journal-title":"Genome Med."},{"key":"2269_CR428","doi-asserted-by":"crossref","unstructured":"Assi, R., Kantarjian, H., Ravandi, F. & Daver, N. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr. Opin. Hematol. 25 111\u2013117 (2018).","DOI":"10.1097\/MOH.0000000000000401"},{"key":"2269_CR429","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams, P. et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125, 1470\u20131481 (2019).","journal-title":"Cancer"},{"key":"2269_CR430","doi-asserted-by":"crossref","unstructured":"Mardiana, S. & Gill, S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front. Oncol. 10, 577285 (2020).","DOI":"10.3389\/fonc.2020.00697"},{"key":"2269_CR431","doi-asserted-by":"publisher","first-page":"108382","DOI":"10.1016\/j.clim.2020.108382","volume":"214","author":"W Song","year":"2020","unstructured":"Song, W. & Zhang, M. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. Clin. Immunol. 214, 108382 (2020).","journal-title":"Clin. Immunol."},{"key":"2269_CR432","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-21-1559","volume":"27","author":"J Lemoine","year":"2021","unstructured":"Lemoine, J., Ruella, M. & Houot, R. Overcoming intrinsic resistance of cancer cells to CAR T-cell killing. Clin. Cancer Res. 27, 6298\u20136306 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2269_CR433","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1042\/BST20150253","volume":"44","author":"H Karlsson","year":"2016","unstructured":"Karlsson, H. Approaches to augment CAR T-cell therapy by targeting the apoptotic machinery. Biochem. Soc. Trans. 44, 371\u2013376 (2016).","journal-title":"Biochem. Soc. Trans."},{"key":"2269_CR434","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-017-0358-y","volume":"9","author":"R Mazzone","year":"2017","unstructured":"Mazzone, R., Zwergel, C., Mai, A. & Valente, S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin. Epigenet.9, 59 (2017).","journal-title":"Clin. Epigenet."},{"key":"2269_CR435","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20696-x","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat. Commun. 12, 409 (2021).","journal-title":"Nat. Commun."},{"key":"2269_CR436","doi-asserted-by":"publisher","first-page":"6975","DOI":"10.1038\/sj.onc.1209678","volume":"25","author":"SR James","year":"2006","unstructured":"James, S. R., Link, P. A. & Karpf, A. R. Epigenetic regulation of X-linked cancer\/germline antigen genes by DNMT1 and DNMT3b. Oncogene 25, 6975\u20136985 (2006).","journal-title":"Oncogene"},{"key":"2269_CR437","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00432-017-2394-6","volume":"143","author":"J Zhou","year":"2017","unstructured":"Zhou, J. et al. Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells. J. Cancer Res. Clin. Oncol. 143, 1371\u20131380 (2017).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2269_CR438","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"2269_CR439","doi-asserted-by":"crossref","unstructured":"Ot\u00e1hal, P. et al. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology 5, e1226723 (2016).","DOI":"10.1080\/2162402X.2015.1115940"},{"key":"2269_CR440","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","volume":"18","author":"M Works","year":"2019","unstructured":"Works, M. et al. Anti\u2013B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide. Mol. Cancer Ther. 18, 2246\u20132257 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"2269_CR441","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai, K. et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J. Hematol. Oncol. 17, 105 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2269_CR442","doi-asserted-by":"crossref","unstructured":"PRODH2-mediated proline metabolism boosts CAR T-cell effector function. Cancer Discov. 12, 1405 (2022).","DOI":"10.1158\/2159-8290.CD-RW2022-054"},{"key":"2269_CR443","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cmet.2022.02.009","volume":"34","author":"L Ye","year":"2022","unstructured":"Ye, L. et al. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab. 34, 595\u2013614.e14 (2022).","journal-title":"Cell Metab."},{"key":"2269_CR444","doi-asserted-by":"crossref","unstructured":"Yang, Q. et al. Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism. Oncoimmunology 11, 2093402 (2022).","DOI":"10.1080\/2162402X.2022.2055703"},{"key":"2269_CR445","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1182\/blood.2024024446","volume":"143","author":"HE Heslop","year":"2024","unstructured":"Heslop, H. E. Data mining for second malignancies after CAR-T. Blood 143, 2023\u20132024 (2024).","journal-title":"Blood"},{"key":"2269_CR446","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton, M. P. et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N. Engl. J. Med. 390, 2047\u20132060 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR447","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","volume":"106","author":"P Strati","year":"2021","unstructured":"Strati, P. et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106, 2667\u20132672 (2021).","journal-title":"Haematologica"},{"key":"2269_CR448","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"M Elsallab","year":"2024","unstructured":"Elsallab, M. et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system. Blood 143, 2099\u20132105 (2024).","journal-title":"Blood"},{"key":"2269_CR449","unstructured":"National Library of Medicine (US). NCT04134117. Tisagenlecleucel in primary CNS lymphoma. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04134117?cond=NCT04134117&rank=1 (2019)."},{"key":"2269_CR450","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1182\/blood-2021-148444","volume":"138","author":"MJ Frigault","year":"2021","unstructured":"Frigault, M. J. et al. Tisagenlecleucel demonstrates safety, efficacy and CNS trafficking in primary CNS lymphoma. Blood 138, 258\u2013258 (2021).","journal-title":"Blood"},{"key":"2269_CR451","doi-asserted-by":"crossref","unstructured":"Dietrich, J. et al. CAR-T cell therapy in recurrent primary CNS lymphoma (PCNSL): a phase 2 clinical trial (S27.009). Neurology 98, S27.009 (2022).","DOI":"10.1212\/WNL.98.18_supplement.3592"},{"key":"2269_CR452","unstructured":"National Library of Medicine (US). NCT03630159. Study of tisagenlecleucel in combination with pembrolizumab in R\/R diffuse large B-cell lymphoma patients (PORTIA). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03630159?cond=tisagenlecleucel&checkSpell=&rank=9 (2018)."},{"key":"2269_CR453","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1182\/bloodadvances.2022007779","volume":"7","author":"U Jaeger","year":"2023","unstructured":"Jaeger, U. et al. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with R\/R DLBCL: phase 1b PORTIA study results. Blood Adv. 7, 2283\u20132286 (2023).","journal-title":"Blood Adv."},{"key":"2269_CR454","unstructured":"National Library of Medicine (US). NCT03876028. Study of tisagenlecleucel in combination with ibrutinib in R\/R diffuse large B-cell lymphoma patients. ClinicalTrials.gov [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT03876028?cond=tisagenlecleucel&checkSpell=&page=2&rank=11 (2019)."},{"key":"2269_CR455","unstructured":"national library of medicine (us). nct06003179. optimizing lymphodepletion to improve outcomes in patients receiving cell therapy with kymriah (LOKI). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06003179?cond=tisagenlecleucel&checkSpell=&page=3&rank=22 (2023)."},{"key":"2269_CR456","unstructured":"National Library of Medicine (US). NCT05310591. Combination of an anti-PD1 antibody with tisagenlecleucel reinfusion in children, adolescents and young adults with acute lymphoblastic leukemia after loss of persistence (CAPTiRALL). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05310591?cond=tisagenlecleucel&checkSpell=&page=2&rank=16 (2022)."},{"key":"2269_CR457","unstructured":"National Library of Medicine (US). NCT03876769. Study of efficacy and safety of tisagenlecleucel in HR B-ALL EOC MRD positive patients (CASSIOPEIA). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03876769?cond=NCT03876769&rank=1 (2018)."},{"key":"2269_CR458","doi-asserted-by":"crossref","unstructured":"Buechner, J. et al. Chimeric antigen receptor T-cell therapy in paediatric B-cell precursor acute lymphoblastic leukaemia: curative treatment option or bridge to transplant? Front. Pediatr. 9 (2022).","DOI":"10.3389\/fped.2021.784024"},{"key":"2269_CR459","unstructured":"National Library of Medicine (US). NCT03568461.Efficacy and safety of tisagenlecleucel in adult patients with refractory or relapsed follicular lymphoma (ELARA). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03568461?cond=NCT03568461&rank=1&tab=results (2018)."},{"key":"2269_CR460","unstructured":"National Library of Medicine (US). NCT04234061. Clinical Trial to Assess The efficacy and safety of the combination of tisagenlecleucel and ibrutinib in mantle cell lymphoma (TARMAC). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04234061?cond=tisagenlecleucel&checkSpell=&page=2&rank=18&tab=table (2020)."},{"key":"2269_CR461","unstructured":"National Library of Medicine (U.S.). NCT02445248. Study of efficacy and safety of CTL019 in adult DLBCL patients (JULIET). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT02445248?cond=NCT02445248&rank=1 (2015)."},{"key":"2269_CR462","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster, S. J. et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 22, 1403\u20131415 (2021).","journal-title":"Lancet Oncol."},{"key":"2269_CR463","unstructured":"National Library of Medicine (US). NCT03610724. Phase II open label trial to determine safety & efficacy of tisagenlecleucel in pediatric non-Hodgkin lymphoma patients. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03610724?cond=NCT03610724&rank=1 (2018)."},{"key":"2269_CR464","unstructured":"National Library of Medicine (U.S.). NCT02228096. Study of efficacy and safety of CTL019 in pediatric ALL patients (ENSIGN). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT02228096?tab=results (2014)."},{"key":"2269_CR465","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1182\/blood-2023-181663","volume":"142","author":"R Awasthi","year":"2023","unstructured":"Awasthi, R. et al. Long term durable responses in relapsed\/refractory (R\/R) ALL, DLBCL, and FL patients treated with tisagenlecleucel and its association with persistence of CAR T-cells. Blood 142, 4872\u20134872 (2023).","journal-title":"Blood"},{"key":"2269_CR466","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/s41375-022-01550-z","volume":"36","author":"TW Laetsch","year":"2022","unstructured":"Laetsch, T. W. et al. Tisagenlecleucel in pediatric and young adult patients with down syndrome-associated relapsed\/refractory acute lymphoblastic leukemia. Leukemia 36, 1508\u20131515 (2022).","journal-title":"Leukemia"},{"key":"2269_CR467","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1182\/bloodadvances.2020003844","volume":"5","author":"K Thudium Mueller","year":"2021","unstructured":"Thudium Mueller, K. et al. Tisagenlecleucel immunogenicity in relapsed\/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Adv. 5, 4980\u20134991 (2021).","journal-title":"Blood Adv."},{"key":"2269_CR468","unstructured":"National Library of Medicine (US). NCT05460533. A second infusion (early reinfusion) of tisagenlecleucel in children and young adults with B-cell acute lymphoblastic leukemia(B-ALL). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05460533?cond=tisagenlecleucel&checkSpell=&page=2&rank=19 (2022)."},{"key":"2269_CR469","unstructured":"National Library of Medicine (US). NCT04225676. Study of efficacy and safety of reinfusion of tisagenlecleucel in pediatric and young adult patients with acute lymphoblastic leukemia (ALL). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04225676?cond=NCT04225676&rank=1 (2020)."},{"key":"2269_CR470","doi-asserted-by":"publisher","first-page":"S262","DOI":"10.1016\/S2152-2650(21)01641-4","volume":"21","author":"MW Boyer","year":"2021","unstructured":"Boyer, M. W. et al. ALL-026: evaluating efficacy and safety of tisagenlecleucel reinfusion following loss of B-cell aplasia in pediatric and young adult patients with acute lymphoblastic leukemia: HESTER phase II study. Clin. Lymphoma Myeloma Leuk. 21, S262\u2013S263 (2021).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2269_CR471","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2020-136340","volume":"136","author":"MW Boyer","year":"2020","unstructured":"Boyer, M. W. et al. HESTER: A phase II study evaluating efficacy and safety of tisagenlecleucel reinfusion in pediatric and young adult patients with acute lymphoblastic leukemia experiencing loss of B-cell aplasia. Blood 136, 23\u201324 (2020).","journal-title":"Blood"},{"key":"2269_CR472","unstructured":"National Library of Medicine (US). NCT04161118. Tisagenlecleucel in elderly patients with first-relapsed or primary refractory aggressive B-cell non-Hodgkin lymphoma (TIGER-CTL019). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04161118?term=tisagenlecleucel&rank=19 (2019)."},{"key":"2269_CR473","unstructured":"National Library of Medicine (US). NCT04156659. Study of tisagenlecleucel in chinese pediatric and young adult subjects with relapsed or refractory B-cell ALL. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04156659?cond=tisagenlecleucel&checkSpell=&page=2&rank=13 (2019)."},{"key":"2269_CR474","unstructured":"National Library of Medicine (US). NCT04456023. Study of tisagenlecleucel in chinese adult patients with relapsed or refractory diffuse large b-cell non-Hodgkin lymphoma (DLBCL). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04456023?cond=tisagenlecleucel&checkSpell=&page=2&rank=17 (2020)."},{"key":"2269_CR475","unstructured":"National Library of Medicine (US). NCT03570892. Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03570892?cond=NCT03570892&rank=1 (2018)."},{"key":"2269_CR476","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop, M. R. et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N. Engl. J. Med. 386, 629\u2013639 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR477","unstructured":"National Library of Medicine (US). NCT05888493. A phase III trial comparing tisagenlecleucel to standard of care (SoC) in adult participants with R\/R follicular lymphoma (LEDA). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05888493?term=tisagenlecleucel&rank=21&tab=table (2023)."},{"key":"2269_CR478","unstructured":"National Library of Medicine (US). NCT04094311. Study of out of specification for tisagenlecleucel. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04094311?cond=tisagenlecleucel&checkSpell=&rank=2.(2021)"},{"key":"2269_CR479","unstructured":"National Library of Medicine (US). NCT05199961. Quality of life of adults with diffuse large B-cell lymphoma treated with tisagenlecleucel. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05199961?term=tisagenlecleucel&rank=22 (2022)."},{"key":"2269_CR480","unstructured":"National Library of Medicine (US). NCT05541341. Effectiveness and safety of tisagenlecleucel therapy in brazilian patients with B-lymphocyte malignancies. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05541341?cond=tisagenlecleucel&checkSpell=&rank=6 (2022)."},{"key":"2269_CR481","unstructured":"National Library of Medicine (US). NCT03153462. Axicabtagene ciloleucel expanded access study (ZUMA-9). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03153462?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=23 (2017)."},{"key":"2269_CR482","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2020-136136","volume":"136","author":"CA Jacobson","year":"2020","unstructured":"Jacobson, C. A. et al. Outcomes of patients (Pts) in ZUMA-9, a multicenter, open-label study of axicabtagene ciloleucel (axi-cel) in relapsed\/refractory large B cell lymphoma (R\/R LBCL) for expanded access and commercial out-of-specification (OOS) product. Blood 136, 2\u20133 (2020).","journal-title":"Blood"},{"key":"2269_CR483","unstructured":"National Library of Medicine (US). NCT04608487. Axi-cel in CNS lymphoma. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04608487?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=15 (2020)."},{"key":"2269_CR484","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2024.42.16_suppl.2006","volume":"42","author":"L Nayak","year":"2024","unstructured":"Nayak, L. et al. A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed\/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL). J. Clin. Oncol. 42, 2006\u20132006 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR485","unstructured":"National Library of Medicine (US). NCT05077527. Immune cell therapy (CAR-T) for the treatment of patients with HIV and B-cell non-Hodgkin lymphoma. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05077527?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=13 (2021)."},{"key":"2269_CR486","unstructured":"National Library of Medicine (US). NCT05794958. Evaluate safety of axicabtagene ciloleucel reinfusion (axi-cel-2) in patients with relapsed and\/or refractory second line high-risk non-Hodgkin lymphoma after standard of care Axi-Cel. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05794958?cond=NCT05794958.%20&rank=1 (2023)."},{"key":"2269_CR487","unstructured":"National Library of Medicine (US). NCT05950802. Optimizing lymphodepletion to improve outcomes in patients receiving cell therapy with yescarta (ODIN). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05950802?cond=yescarta&rank=1 (2023)."},{"key":"2269_CR488","unstructured":"National Library of Medicine (US). NCT03704298. Safety and efficacy of axicabtagene ciloleucel in combination with utomilumab in adults with refractory large B-cell lymphoma (ZUMA-11). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03704298?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=21 (2018)."},{"key":"2269_CR489","unstructured":"National Library of Medicine (US). NCT04314843. Study of lenzilumab and axicabtagene ciloleucel in participants with relapsed or refractory large B-cell lymphoma (ZUMA-19). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04314843?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=17 (2020)."},{"key":"2269_CR490","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-135988","volume":"136","author":"SS Kenderian","year":"2020","unstructured":"Kenderian, S. S. et al. ZUMA-19: A phase 1\/2 multicenter study of lenzilumab use with axicabtagene ciloleucel (axi-cel) in patients (Pts) with relapsed or refractory large B cell lymphoma (R\/R LBCL). Blood 136, 6\u20137 (2020).","journal-title":"Blood"},{"key":"2269_CR491","doi-asserted-by":"publisher","first-page":"10318","DOI":"10.1182\/blood-2022-167688","volume":"140","author":"OO Oluwole","year":"2022","unstructured":"Oluwole, O. O. et al. ZUMA-19: A phase 1\/2 study of axicabtagene ciloleucel plus lenzilumab in patients with relapsed or refractory large B-cell lymphoma. Blood 140, 10318\u201310320 (2022).","journal-title":"Blood"},{"key":"2269_CR492","unstructured":"National Library of Medicine (US). NCT03105336. A phase 2 multicenter study of axicabtagene ciloleucel in subjects with relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03105336?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=24 (2017)."},{"key":"2269_CR493","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu, S. S. et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 143, 496\u2013506 (2024).","journal-title":"Blood"},{"key":"2269_CR494","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2021014375","volume":"140","author":"P Ghione","year":"2022","unstructured":"Ghione, P. et al. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma. Blood 140, 851\u2013860 (2022).","journal-title":"Blood"},{"key":"2269_CR495","unstructured":"Leslie, L. et al. P1159 ZUMA-24 Preliminary analysis: a phase 2 study of axicabtagene ciloleucel in the outpatient setting with prophylactic corticosteroids in patients with relapsed\/refractory large B-cell lymphoma. In Eha2024 2093402 (2024)."},{"key":"2269_CR496","doi-asserted-by":"publisher","first-page":"e50042ff","DOI":"10.1097\/01.HS9.0000976104.50042.ff","volume":"7","author":"L Leslie","year":"2023","unstructured":"Leslie, L. et al. Pb2346: ZUMA-24: a phase 2, open-label, multicenter study of axicabtagene ciloleucel in patients with relapsed\/refractory large B-cell lymphoma given with corticosteroids in the outpatient setting. Hemasphere 7, e50042ff (2023).","journal-title":"Hemasphere"},{"key":"2269_CR497","unstructured":"National Library of Medicine (US). NCT05459571. Study of axicabtagene ciloleucel given with steroids in participants with relapsed or refractory large B-cell lymphoma (ZUMA-24). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05459571?cond=NCT05459571&rank=1."},{"key":"2269_CR498","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1182\/blood-2019-126369","volume":"134","author":"SS Neelapu","year":"2019","unstructured":"Neelapu, S. S. et al. A phase 2, open-label, multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel in combination with either rituximab or lenalidomide in patients with refractory large B-cell lymphoma (ZUMA-14). Blood 134, 4093\u20134093 (2019).","journal-title":"Blood"},{"key":"2269_CR499","doi-asserted-by":"publisher","first-page":"7567","DOI":"10.1200\/JCO.2022.40.16_suppl.7567","volume":"40","author":"P Strati","year":"2022","unstructured":"Strati, P. et al. Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): outcomes of the phase 2 ZUMA-14 study. J. Clin. Oncol. 40, 7567\u20137567 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR500","unstructured":"National Library of Medicine (US). NCT04002401. Safety and efficacy of axicabtagene ciloleucel in combination with rituximab in participants with refractory large B-cell lymphoma (ZUMA-14). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04002401?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=18 (2019)."},{"key":"2269_CR501","unstructured":"National Library of Medicine (US). NCT03761056. Study to evaluate the efficacy and safety of axicabtagene ciloleucel as first-line therapy in participants with high-risk large B-cell lymphoma. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/search?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate (2018)."},{"key":"2269_CR502","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2021-148009","volume":"138","author":"SS Neelapu","year":"2021","unstructured":"Neelapu, S. S. et al. Primary analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). Blood 138, 739\u2013739 (2021).","journal-title":"Blood"},{"key":"2269_CR503","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2020-134449","volume":"136","author":"SS Neelapu","year":"2020","unstructured":"Neelapu, S. S. et al. Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL). Blood 136, 49\u201349 (2020).","journal-title":"Blood"},{"key":"2269_CR504","doi-asserted-by":"publisher","first-page":"TPS7574","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7574","volume":"37","author":"SS Neelapu","year":"2019","unstructured":"Neelapu, S. S. et al. ZUMA-12: a phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL). J. Clin. Oncol. 37, TPS7574\u2013TPS7574 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR505","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","volume":"28","author":"SS Neelapu","year":"2022","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat. Med 28, 735\u2013742 (2022).","journal-title":"Nat. Med"},{"key":"2269_CR506","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood-2023-174510","volume":"142","author":"JC Chavez","year":"2023","unstructured":"Chavez, J. C. et al. 3-year analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). Blood 142, 894\u2013894 (2023).","journal-title":"Blood"},{"key":"2269_CR507","unstructured":"National Library of Medicine (US). NCT06218602. Pilot trial of fecal microbiota transplantation for lymphoma patients receiving axicabtagene ciloleucel therapy. ClinicalTrials.gov [Internet https:\/\/clinicaltrials.gov\/study\/NCT06218602?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=4 (2024)."},{"key":"2269_CR508","unstructured":"National Library of Medicine (US). NCT06043323. A phase II study of axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in combination with radiotherapy (RT) in relapsed\/refractory follicular lymphoma. ClinicalTrials.gov [Internet https:\/\/clinicaltrials.gov\/study\/NCT06043323?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=6 (2023)."},{"key":"2269_CR509","unstructured":"National Library of Medicine (US). NCT06213311. A study of axicabtagene ciloleucel and glofitamab as second-line therapy for relapsed or refractory patients with large B cell lymphoma. ClinicalTrials.gov [Internet https:\/\/clinicaltrials.gov\/study\/NCT06213311?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=5 (2024)."},{"key":"2269_CR510","unstructured":"National Library of Medicine (US). NCT03391466. Study of effectiveness of axicabtagene ciloleucel compared to standard of care therapy in patients with relapsed\/refractory diffuse large B cell lymphoma (ZUMA-7). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03391466?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=22 (2017)."},{"key":"2269_CR511","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2022-158303","volume":"140","author":"A Ghobadi","year":"2022","unstructured":"Ghobadi, A. et al. Outcomes of subsequent anti-lymphoma therapies in patients (pts) with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) or standard of care (SOC) in the second-line (2L) ZUMA-7 study. Blood 140, 1595\u20131597 (2022).","journal-title":"Blood"},{"key":"2269_CR512","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood-2022-158492","volume":"140","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Association of metabolic tumor volume (MTV) and clinical outcomes in second-line (2L) relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL) following axicabtagene ciloleucel (axi-cel) versus standard-of-care (Soc) therapy in ZUMA-7. Blood 140, 638\u2013640 (2022).","journal-title":"Blood"},{"key":"2269_CR513","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin, J. R. et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N. Engl. J. Med. 389, 148\u2013157 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2269_CR514","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-22-3136","volume":"29","author":"JR Westin","year":"2023","unstructured":"Westin, J. R. et al. Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed\/refractory large B-cell lymphoma. Clin. Cancer Res. 29, 1894\u20131905 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2269_CR515","unstructured":"National Library of Medicine (US). NCT05605899. Study to compare axicabtagene ciloleucel with standard of care therapy as first-line treatment in participants with high-risk large B-cell lymphoma (ZUMA-23). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05605899?cond=NCT05605899&rank=1 (2022)."},{"key":"2269_CR516","unstructured":"National Library of Medicine (US). NCT05371093. Study of axicabtagene ciloleucel versus standard of care therapy in participants with relapsed\/refractory follicular lymphoma (ZUMA-22). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05371093?cond=NCT05371093&rank=1 (2022)."},{"key":"2269_CR517","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000971324.63506.62","volume":"7","author":"IW Flinn","year":"2023","unstructured":"Flinn, I. W. et al. P1107: ZUMA-22: a phase 3, randomized controlled study of axicabtagene ciloleucel versus standard-of-care therapy in patients with relapsed or refractory follicular lymphoma. Hemasphere 7, e6350662 (2023).","journal-title":"Hemasphere"},{"key":"2269_CR518","unstructured":"National Library of Medicine (US). NCT06609304. Axicabtagene ciloleucel for consolidation after first-line treatment of high-risk large B-cell lymphoma (axi-cel). ClinicalTrials.gov [Internet https:\/\/clinicaltrials.gov\/study\/NCT06609304?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=1 (2024)."},{"key":"2269_CR519","unstructured":"National Library of Medicine (US). NCT05800067. Axi-cel retreatment in relapsed\/refractory LBCL. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05800067?cond=Axicabtagene%20ciloleucel&sort=StudyFirstPostDate&rank=7 (2022)."},{"key":"2269_CR520","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1182\/blood-2023-174273","volume":"142","author":"A Goy","year":"2023","unstructured":"Goy, A. et al. Outcomes of patients with relapsed\/refractory mantle cell lymphoma (R\/R MCL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-2 and ZUMA-18, an expanded access study. Blood 142, 106\u2013106 (2023).","journal-title":"Blood"},{"key":"2269_CR521","unstructured":"National Library of Medicine (US). NCT04162756. Study of brexucabtagene autoleucel (KTE-X19) for the treatment of individuals with relapsed\/refractory B-cell malignancies (ZUMA-18). ClinicalTrials.gov [Internet] (2019)."},{"key":"2269_CR522","unstructured":"NCT05776134. Expanded access study for the treatment of patients with commercially out-of-specification brexucabtagene autoleucel. ClinicalTrials.gov [Internet]."},{"key":"2269_CR523","unstructured":"National Library of Medicine (US). NCT05993949. Study of brexucabtagene autoleucel plus dasatinib in adults with acute lymphoblastic leukemia. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05993949?cond=brexucabtagene%20autoleucel&rank=3 (2023)."},{"key":"2269_CR524","doi-asserted-by":"publisher","first-page":"7454","DOI":"10.1182\/blood-2022-167868","volume":"140","author":"MS Davids","year":"2022","unstructured":"Davids, M. S. et al. ZUMA-8: a phase 1 study of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed\/refractory chronic lymphocytic leukemia. Blood 140, 7454\u20137456 (2022).","journal-title":"Blood"},{"key":"2269_CR525","doi-asserted-by":"publisher","first-page":"TPS7566","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7566","volume":"37","author":"I Flinn","year":"2019","unstructured":"Flinn, I. et al. ZUMA-8: a phase 1\/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL). J. Clin. Oncol. 37, TPS7566\u2013TPS7566 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR526","unstructured":"National Library of Medicine (US). NCT03624036. Study to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in people with relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (ZUMA-8). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03624036?cond=brexucabtagene%20autoleucel&rank=9#publications (2018)."},{"key":"2269_CR527","unstructured":"National Library of Medicine (U.S.). NCT02625480. Study evaluating brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed\/refractory B-precursor acute lymphoblastic leukemia or relapsed\/refractory B-cell non-Hodgkin lymphoma (ZUMA-4). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT02625480?cond=brexucabtagene%20autoleucel&rank=10 (2015)."},{"key":"2269_CR528","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3324\/haematol.2022.280678","volume":"108","author":"AS Wayne","year":"2022","unstructured":"Wayne, A. S. et al. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed\/refractory acute lymphoblastic leukemia. Haematologica 108, 747\u2013760 (2022).","journal-title":"Haematologica"},{"key":"2269_CR529","unstructured":"National Library of Medicine (U.S.). NCT02614066. A study evaluating the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adult subjects with relapsed\/refractory B-precursor acute lymphoblastic leukemia (ZUMA-3) (ZUMA-3). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT02614066?cond=NCT02614066&rank=1 (2015)."},{"key":"2269_CR530","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","volume":"138","author":"BD Shah","year":"2021","unstructured":"Shah, B. D. et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood 138, 11\u201322 (2021).","journal-title":"Blood"},{"key":"2269_CR531","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398, 491\u2013502 (2021).","journal-title":"Lancet"},{"key":"2269_CR532","unstructured":"National Library of Medicine (US). NCT06287229. Phase Ib\/II study assessing the clinical activity and safety of brexucabtagene autoleucel as a consolidation in patients with relapsed\/refractory (R\/R) and newly diagnosed b-cell acute lymphocytic leukemia (ALL) post cytoreduction with mini-HCVD-inotuzumab-blinatumomab\/HCVAD-inotuzumab-blinatumomab. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06287229?cond=brexucabtagene%20autoleucel&rank=2 (2024)."},{"key":"2269_CR533","unstructured":"National Library of Medicine (US). NCT05537766. Study of brexucabtagene autoleucel in adults with rare B-cell malignancies (ZUMA-25). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05537766?cond=brexucabtagene%20autoleucel&rank=5 (2022)."},{"key":"2269_CR534","doi-asserted-by":"publisher","first-page":"TPS7075","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS7075","volume":"34","author":"AS Wayne","year":"2016","unstructured":"Wayne, A. S. et al. ZUMA-4: A phase 1\/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed\/refractory B-precursor acute lymphoblastic leukemia (R\/R ALL). J. Clin. Oncol. 34, TPS7075\u2013TPS7075 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR535","doi-asserted-by":"publisher","first-page":"TPS3102","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3102","volume":"36","author":"M Wang","year":"2018","unstructured":"Wang, M. et al. ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed\/refractory mantle cell lymphoma. J. Clin. Oncol. 36, TPS3102\u2013TPS3102 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR536","unstructured":"National Library of Medicine (U.S.). NCT02601313. Study of brexucabtagene autoleucel (KTE-X19) in participants with relapsed\/refractory mantle cell lymphoma (cohort 1 and cohort 2) (ZUMA-2). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT02601313?cond=brexucabtagene%20autoleucel&rank=12 (2015)."},{"key":"2269_CR537","unstructured":"National Library of Medicine (US). NCT06553872. Phase 2 open label randomized study of pirtobrutinib and brexucabtagene autoleucel in R\/R MCL. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06553872?cond=brexucabtagene%20autoleucel&rank=1 (2024)."},{"key":"2269_CR538","unstructured":"National Library of Medicine (US). NCT04880434. Study of brexucabtagene autoleucel (KTE-X19) in participants with relapsed\/refractory mantle cell lymphoma (cohort 3) (ZUMA-2). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04880434?cond=NCT04880434&rank=1 (2021)."},{"key":"2269_CR539","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1182\/blood-2024-198021","volume":"144","author":"T van Meerten","year":"2024","unstructured":"van Meerten, T. et al. Primary analysis of ZUMA-2 cohort 3: brexucabtagene autoleucel (brexu-cel) in patients (pts) with relapsed\/refractory mantle cell lymphoma (R\/R MCL) who were naive to bruton tyrosine kinase inhibitors (BTKi). Blood 144, 748\u2013748 (2024).","journal-title":"Blood"},{"key":"2269_CR540","unstructured":"National Library of Medicine (US). NCT03274219. Study of bb21217 in multiple myeloma. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03274219?cond=idecabtagene%20vicleucel&rank=17 (2017)."},{"key":"2269_CR541","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2020-140410","volume":"136","author":"M Alsina","year":"2020","unstructured":"Alsina, M. et al. Updated results from the phase I CRB-402 study of anti-Bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes. Blood 136, 25\u201326 (2020).","journal-title":"Blood"},{"key":"2269_CR542","unstructured":"National Library of Medicine (US). NCT04771078. Expanded access protocol (EAP) for participants receiving idecabtagene vicleucel that is nonconforming for commercial release. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04771078?cond=NCT04771078&rank=1."},{"key":"2269_CR543","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1182\/blood-2024-200829","volume":"144","author":"B Paul","year":"2024","unstructured":"Paul, B. et al. Idecabtagene vicleucel (ide-cel) in patients (pts) with newly diagnosed multiple myeloma (NDMM) with an inadequate response to front-line autologous stem cell transplantation (ASCT): karMMa-2 cohort 2c extended follow-up. Blood 144, 3388\u20133388 (2024).","journal-title":"Blood"},{"key":"2269_CR544","unstructured":"National Library of Medicine (US). NCT06048250. Mezigdomide (CC-92480) post idecabtagene vicleucel in treating patients with relapsed multiple myeloma. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06048250?cond=idecabtagene%20vicleucel&rank=7 (2023)."},{"key":"2269_CR545","doi-asserted-by":"publisher","first-page":"8016","DOI":"10.1200\/JCO.2021.39.15_suppl.8016","volume":"39","author":"JLD Anderson","year":"2021","unstructured":"Anderson, J. L. D. et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. J. Clin. Oncol. 39, 8016\u20138016 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR546","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1182\/blood-2021-147412","volume":"138","author":"NS Raje","year":"2021","unstructured":"Raje, N. S. et al. KarMMa-7, a phase 1\/2, dose-finding and dose-expansion study of combination therapies with idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy for relapsed\/refractory multiple myeloma (rrmm). Blood 138, 4830\u20134830 (2021).","journal-title":"Blood"},{"key":"2269_CR547","unstructured":"National Library of Medicine (US). NCT04855136. Safety and efficacy of bb2121 (ide-cel) combinations in multiple myeloma (KarMMa-7). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04855136?cond=idecabtagene%20vicleucel&rank=13 (2021)."},{"key":"2269_CR548","unstructured":"National Library of Medicine (US). NCT06518551. Elotuzumab + iberdomide + dexamethasone post ide-cel in rrmm. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06518551?cond=idecabtagene%20vicleucel&rank=3 (2024)."},{"key":"2269_CR549","unstructured":"National Library of Medicine (US). NCT05032820. MM CAR-T to upgrade response BMTCTN1902. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05032820?cond=idecabtagene%20vicleucel&rank=12 (2021)."},{"key":"2269_CR550","unstructured":"National Library of Medicine (US). NCT06523621. Nivolumab in multiple myeloma patients after idecabtagene vicleucel. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06523621?cond=idecabtagene%20vicleucel&rank=2 (2024)."},{"key":"2269_CR551","unstructured":"National Library of Medicine (US). NCT05393804. A study of whether ide-cel (bb2121) can be made from people with multiple myeloma who have had a hematopoietic cell transplant. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05393804?cond=idecabtagene%20vicleucel&rank=10 (2022)."},{"key":"2269_CR552","unstructured":"National Library of Medicine (US). NCT06179888. Iberdomide versus observation off therapy after idecabtagene vicleucel CAR-T for multiple myeloma. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06179888?cond=idecabtagene%20vicleucel&rank=4 (2023)."},{"key":"2269_CR553","unstructured":"National Library of Medicine (US). NCT06045806. A study to compare the efficacy and safety of idecabtagene vicleucel with lenalidomide maintenance therapy versus lenalidomide maintenance therapy alone in adult participants with newly diagnosed multiple myeloma who have suboptimal response after autologous stem cell transplantation (KarMMa-9). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06045806?cond=idecabtagene%20vicleucel&rank=8 (2023)."},{"key":"2269_CR554","doi-asserted-by":"publisher","first-page":"S562","DOI":"10.1016\/S2152-2650(24)01690-2","volume":"24","author":"N Raje","year":"2024","unstructured":"Raje, N. et al. MM-493 Efficacy and safety of idecabtagene vicleucel (ide-cel) with lenalidomide (R) maintenance versus R maintenance alone in adult patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplantation (ASCT): phase 3 KarMMa-9 trial. Clin. Lymphoma Myeloma Leuk. 24, S562\u2013S563 (2024).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2269_CR555","unstructured":"National Library of Medicine (US). NCT06698887. A study to evaluate the long-term safety of idecabtagene vicleucel treatment in adults with newly diagnosed multiple myeloma in korea. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06698887?cond=idecabtagene%20vicleucel&rank=1 (2024)."},{"key":"2269_CR556","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson, J. S. et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood 143, 404\u2013416 (2024).","journal-title":"Blood"},{"key":"2269_CR557","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 141, 1675\u20131684 (2023).","journal-title":"Blood"},{"key":"2269_CR558","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","volume":"36","author":"JS Abramson","year":"2018","unstructured":"Abramson, J. S. et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL. J. Clin. Oncol. 36, 7505\u20137505 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR559","unstructured":"National Library of Medicine (US). NCT02631044. Study evaluating the safety and pharmacokinetics of JCAR017 in B-cell non-Hodgkin lymphoma (TRANSCEND-NHL-001). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT02631044?intr=Lisocabtagene%20maraleucel&rank=20 (2015)."},{"key":"2269_CR560","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cpt.2561","volume":"112","author":"K Ogasawara","year":"2022","unstructured":"Ogasawara, K. et al. In vivo cellular expansion of lisocabtagene maraleucel and association with efficacy and safety in relapsed\/refractory large B-cell lymphoma. Clin. Pharm. Ther. 112, 81\u201389 (2022).","journal-title":"Clin. Pharm. Ther."},{"key":"2269_CR561","unstructured":"National Library of Medicine (US). NCT05075603. Relapsed\/refractory large B-cell lymphoma with NT-I7 Post-CD19 CAR T-cell therapy. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05075603?cond=NCT05075603&rank=1 (2021)."},{"key":"2269_CR562","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1182\/blood.2021011895","volume":"139","author":"T Siddiqi","year":"2022","unstructured":"Siddiqi, T. et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL. Blood 139, 1794\u20131806 (2022).","journal-title":"Blood"},{"key":"2269_CR563","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi, T. et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study. Lancet 402, 641\u2013654 (2023).","journal-title":"Lancet"},{"key":"2269_CR564","unstructured":"National Library of Medicine (US). NCT03331198. Study evaluating safety and efficacy of JCAR017 in subjects with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03331198?intr=Lisocabtagene%20maraleucel&rank=19 (2017)."},{"key":"2269_CR565","unstructured":"National Library of Medicine (US). NCT03743246. A study to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed\/refractory (R\/R) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03743246?cond=jcar017&sort=StudyFirstPostDate&limit=25&rank=5 (2018)."},{"key":"2269_CR566","unstructured":"National Library of Medicine (US). NCT03483103. Lisocabtagene maraleucel (JCAR017) as SECOND-LINE THERApy (TRANSCEND-PILOT-017006). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03483103?intr=Lisocabtagene%20maraleucel&rank=18 (2018)."},{"key":"2269_CR567","doi-asserted-by":"crossref","unstructured":"Ernst, M. et al. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database of Systematic Reviews (2021).","DOI":"10.1002\/14651858.CD013365.pub2"},{"key":"2269_CR568","doi-asserted-by":"publisher","first-page":"10430","DOI":"10.1182\/blood-2022-159686","volume":"140","author":"N Ghosh","year":"2022","unstructured":"Ghosh, N. et al. Comparative effectiveness of lisocabtagene maraleucel (liso-cel) in PILOT in patients (pt) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL) for whom transplant was not intended (TNI) versus conventional second-line (2L) chemotherapy regimens in the real world. Blood 140, 10430\u201310431 (2022).","journal-title":"Blood"},{"key":"2269_CR569","unstructured":"National Library of Medicine (US). NCT03484702. Trial to determine the efficacy and safety of JCAR017 in adult participants with aggressive B-cell non-Hodgkin lymphoma (TRANSCENDWORLD). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03484702?intr=Lisocabtagene%20maraleucel&rank=17&tab=results (2018)."},{"key":"2269_CR570","unstructured":"National Library of Medicine (US). NCT03744676. A safety trial of lisocabtagene maraleucel (JCAR017) for relapsed and refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting (TRANSCEND-OUTREACH-007). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03744676?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=10 (2018)."},{"key":"2269_CR571","doi-asserted-by":"publisher","first-page":"e19513","DOI":"10.1200\/JCO.2021.39.15_suppl.e19513","volume":"39","author":"JE Godwin","year":"2021","unstructured":"Godwin, J. E. et al. Outreach: preliminary safety and efficacy results from a phase 2 study of lisocabtagene maraleucel (liso-cel) in the nonuniversity setting. J. Clin. Oncol. 39, e19513\u2013e19513 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR572","doi-asserted-by":"publisher","first-page":"6114","DOI":"10.1182\/bloodadvances.2024013254","volume":"8","author":"Y Linhares","year":"2024","unstructured":"Linhares, Y. et al. OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R\/R LBCL. Blood Adv. 8, 6114\u20136126 (2024).","journal-title":"Blood Adv."},{"key":"2269_CR573","unstructured":"National Library of Medicine (US). NCT05583149. Acalabrutinib + liso-cel in R\/R aggressive B-cell lymphomas. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05583149?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=7 (2022)."},{"key":"2269_CR574","unstructured":"National Library of Medicine (US). NCT05672173. Lisocabtagene maraleucel, nivolumab and ibrutinib for the treatment of richter\u2019s transformation. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05672173?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=4 (2023)."},{"key":"2269_CR575","unstructured":"National Library of Medicine (US). NCT05873712. Zanubrutinib and lisocabtagene maraleucel for the treatment of Richter\u2019s syndrome. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05873712?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=3 (2023)."},{"key":"2269_CR576","unstructured":"National Library of Medicine (US). NCT04245839. A study to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL) (TRANSCEND FL). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04245839?cond=jcar017&sort=StudyFirstPostDate&limit=25&rank=3 (2020)."},{"key":"2269_CR577","unstructured":"National Library of Medicine (US). NCT03575351. A study to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (TRANSFORM). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03575351?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=11&tab=results (2018)."},{"key":"2269_CR578","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399, 2294\u20132308 (2022).","journal-title":"Lancet"},{"key":"2269_CR579","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1200\/JCO.2024.42.16_suppl.7013","volume":"42","author":"MK Kamdar","year":"2024","unstructured":"Kamdar, M. K. et al. Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R\/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. J. Clin. Oncol. 42, 7013\u20137013 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR580","unstructured":"National Library of Medicine (US). NCT06313996. A study to evaluate the efficacy and safety of liso-cel compared to standard of care in adults with relapsed or refractory follicular lymphoma. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06313996?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=1 (2024)."},{"key":"2269_CR581","unstructured":"National Library of Medicine (US). NCT06205290. A study to compare the efficacy and safety of lisocabtagene maraleucel vs investigator\u2019s choice options in adult participants with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, whose disease has failed treatment with both BTKi and BCL2i therapies. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06205290?cond=Lisocabtagene%20maraleucel&sort=StudyFirstPostDate&limit=25&page=1&rank=2 (2023)."},{"key":"2269_CR582","unstructured":"National Library of Medicine (US). NCT06623630. Lymphodepleting total body irradiation (TBI) plus cyclophosphamide prior to ciltacabtagene autoleucel (carvykti; cilta-cel) for multiple myeloma (MM) patients with impaired renal function. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06623630?cond=ciltacabtagene%20autoleucel&rank=1 (2024)."},{"key":"2269_CR583","unstructured":"National Library of Medicine (U.S.). NCT03090659. LCAR-B38M Cells in treating relapsed\/refractory (R\/R) multiple myeloma (LEGEND-2). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03090659?cond=ciltacabtagene%20autoleucel&sort=StudyFirstPostDate&limit=25&rank=15 (2017)."},{"key":"2269_CR584","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"W-H Zhao","year":"2022","unstructured":"Zhao, W.-H. et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J. Hematol. Oncol. 15, 86 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2269_CR585","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"W-H Zhao","year":"2018","unstructured":"Zhao, W.-H. et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J. Hematol. Oncol. 11, 141 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2269_CR586","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","volume":"17","author":"J Xu","year":"2024","unstructured":"Xu, J. et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J. Hematol. Oncol. 17, 23 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2269_CR587","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1111\/bjh.19340","volume":"204","author":"R Liu","year":"2024","unstructured":"Liu, R. et al. Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA -specific CAR-T therapy: A retrospective analysis of LEGEND-2. Br. J. Haematol. 204, 1780\u20131789 (2024).","journal-title":"Br. J. Haematol."},{"key":"2269_CR588","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"2269_CR589","unstructured":"National Library of Medicine (US). NCT03548207. A study of JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in participants with relapsed or refractory multiple myeloma (CARTITUDE-1). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03548207?cond=ciltacabtagene%20autoleucel&sort=StudyFirstPostDate&limit=25&rank=14 (2018)."},{"key":"2269_CR590","unstructured":"National Library of Medicine (US). NCT05347485. A study of JNJ-68284528 out-of-specification (OOS) for commercial release in participants with multiple myeloma. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05347485?cond=ciltacabtagene%20autoleucel&rank=6 (2022)."},{"key":"2269_CR591","unstructured":"National Library of Medicine (US). NCT03758417. A study of LCAR-B38M CAR-T cells, a chimeric antigen receptor T-cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in chinese participants with relapsed or refractory multiple myeloma (CARTIFAN-1). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT03758417?cond=ciltacabtagene%20autoleucel&sort=StudyFirstPostDate&limit=25&rank=13 (2018)."},{"key":"2269_CR592","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.22.00690","volume":"41","author":"J-Q Mi","year":"2023","unstructured":"Mi, J.-Q. et al. Phase II, open-label study of ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor\u2013T-cell therapy, in chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1). J. Clin. Oncol. 41, 1275\u20131284 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR593","unstructured":"National Library of Medicine (US). NCT04133636. A study of JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in Participants with multiple myeloma (CARTITUDE-2). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04133636?cond=ciltacabtagene%20autoleucel&rank=12 (2019)."},{"key":"2269_CR594","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen, A. D. et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 141, 219\u2013230 (2023).","journal-title":"Blood"},{"key":"2269_CR595","unstructured":"National Library of Medicine (US). NCT06550895. A study of ciltacabtagene autoleucel and talquetamab for the treatment of participants with high-risk multiple myeloma (MonumenTAL-8). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06550895?cond=ciltacabtagene%20autoleucel&rank=4 (2024)."},{"key":"2269_CR596","unstructured":"National Library of Medicine (US). NCT06574126. Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma (CAR-HiRiSMM). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06574126?cond=ciltacabtagene%20autoleucel&rank=3 (2024)."},{"key":"2269_CR597","unstructured":"National Library of Medicine (US). NCT06577025. A study of different sequences of cilta-cel, talquetamab in combination with daratumumab and teclistamab in combination with daratumumab following induction with daratumumab, bortezomib, lenalidomide and dexamethasone in participants with standard-risk newly diagnosed multiple myeloma (aMMbition). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT06577025?cond=ciltacabtagene%20autoleucel&rank=2 (2024)."},{"key":"2269_CR598","unstructured":"National Library of Medicine (US). NCT04181827. A study comparing JNJ-68284528, a CAR-T therapy directed against B-cell maturation antigen (BCMA), versus pomalidomide, bortezomib and dexamethasone (pvd) or daratumumab, pomalidomide and dexamethasone (DPd) in participants with relapsed and lenalidomide-refractory multiple myeloma (CARTITUDE-4). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04181827?cond=ciltacabtagene%20autoleucel&rank=11 (2019)."},{"key":"2269_CR599","unstructured":"National Library of Medicine (US). NCT04923893. A study of bortezomib, lenalidomide and dexamethasone (VRd) followed by cilta-cel, a CAR-T therapy directed against BCMA versus VRd followed by lenalidomide and dexamethasone (Rd) therapy in participants with newly diagnosed multiple myeloma for whom ASCT is not planned as initial therapy (CARTITUDE-5). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT04923893?cond=ciltacabtagene%20autoleucel&rank=9 (2021)."},{"key":"2269_CR600","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1182\/blood-2021-146210","volume":"138","author":"D Dytfeld","year":"2021","unstructured":"Dytfeld, D. et al. Bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel versus Vrd followed by lenalidomide and dexamethasone (Rd) Maintenance in patients with newly diagnosed multiple myeloma not intended for transplant: a randomized, phase 3 study (CARTITUDE-5). Blood 138, 1835\u20131835 (2021).","journal-title":"Blood"},{"key":"2269_CR601","unstructured":"National Library of Medicine (US). NCT05257083. A study of daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by ciltacabtagene autoleucel versus daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by autologous stem cell transplant (ASCT) in participants with newly diagnosed multiple myeloma (CARTITUDE-6). ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05257083?cond=ciltacabtagene%20autoleucel&rank=7 (2022)."},{"key":"2269_CR602","unstructured":"National Library of Medicine (US). NCT05201781. A long-term study for participants previously treated with ciltacabtagene autoleucel. ClinicalTrials.gov [Internet] https:\/\/clinicaltrials.gov\/study\/NCT05201781?cond=ciltacabtagene%20autoleucel&rank=8 (2022)."},{"key":"2269_CR603","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2022-168877","volume":"140","author":"G Ehninger","year":"2022","unstructured":"Ehninger, G. et al. Phase 1 dose escalation study of the rapidly switchable universal CAR-T therapy Unicar-T-CD123 in relapsed\/refractory AML. Blood 140, 2367\u20132368 (2022).","journal-title":"Blood"},{"key":"2269_CR604","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1182\/blood.2020009759","volume":"137","author":"M Wermke","year":"2021","unstructured":"Wermke, M. et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML. Blood 137, 3145\u20133148 (2021).","journal-title":"Blood"},{"key":"2269_CR605","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1182\/blood-2019-128436","volume":"134","author":"A Feldmann","year":"2019","unstructured":"Feldmann, A. et al. A novel revcar platform for switchable and gated tumor targeting. Blood 134, 5611\u20135611 (2019).","journal-title":"Blood"},{"key":"2269_CR606","doi-asserted-by":"crossref","unstructured":"A. Ehninger, et al. Preclinical characterization of switchable allogeneic chimeric antigen receptor T cells to support first in human clinical study in CD123-positive hematologic and lymphatic malignancies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4095.","DOI":"10.1158\/1538-7445.AM2023-4095"},{"key":"2269_CR607","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1182\/blood-2021-152692","volume":"138","author":"DA Sallman","year":"2021","unstructured":"Sallman, D. A. et al. Phase 1\/1b safety study of Prgn-3006 Ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes. Blood 138, 825 (2021).","journal-title":"Blood"},{"key":"2269_CR608","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50485-9","volume":"15","author":"S Zuo","year":"2024","unstructured":"Zuo, S. et al. C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial. Nat. Commun. 15, 6155 (2024).","journal-title":"Nat. Commun."},{"key":"2269_CR609","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","volume":"23","author":"Q Wang","year":"2015","unstructured":"Wang, Q. et al. Treatment of CD33-directed Chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol. Ther. 23, 184\u2013191 (2015).","journal-title":"Mol. Ther."},{"key":"2269_CR610","doi-asserted-by":"crossref","unstructured":"Shah N., et al. G. Phase 1\/2 study of donor-derived anti-CD33 chimeric antigen receptor expressing T cells (VCAR33 ALLO) in patients with relapsed or refractory acute myeloid leukemia after allogeneic hematopoietic cell transplantation (trial in progress). Presented at the 65 th ASH annual meeting and exposition; December 9-12, San Diego, USA. 2023. Abstract nr 4862.","DOI":"10.1182\/blood-2023-180990"},{"key":"2269_CR611","doi-asserted-by":"crossref","unstructured":"Canesin G., et al. G-CSF\/plerixafor dual-mobilized donor derived CD33CAR T-cells as potent and effective AML therapy in pre-clinical models. Presented at 63rd ASH annual meeting & exposition, December 11\u201314, 2021. Abstract nr 1716.","DOI":"10.1182\/blood-2021-153868"},{"key":"2269_CR612","doi-asserted-by":"crossref","unstructured":"Moeller R, K. S. S. J. Construction and evaluation of interleukin 3 (IL3)-zetakine\u2013redirected cytolytic T cells for treatment of CD123-expressing acute myeloid leukemia. Presented at SITC 2021, November 10\u201314, 2021. Abstract nr 871.","DOI":"10.1136\/jitc-2021-SITC2021.871"},{"key":"2269_CR613","doi-asserted-by":"publisher","first-page":"TPS7078","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7078","volume":"40","author":"TM Cooper","year":"2022","unstructured":"Cooper, T. M. et al. Pediatric and young adult leukemia adoptive therapy (PLAT)-08: A phase 1 study of SC-DARIC33 in pediatric and young adults with relapsed or refractory CD33+ AML. J. Clin. Oncol. 40, TPS7078\u2013TPS7078 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR614","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","volume":"32","author":"JC Petrov","year":"2018","unstructured":"Petrov, J. C. et al. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia 32, 1317\u20131326 (2018).","journal-title":"Leukemia"},{"key":"2269_CR615","doi-asserted-by":"publisher","first-page":"TPS6586","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS6586","volume":"42","author":"NG Daver","year":"2024","unstructured":"Daver, N. G. et al. A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed\/refractory acute myeloid leukemia (AMpLify). J. Clin. Oncol. 42, TPS6586\u2013TPS6586 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR616","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","volume":"132","author":"F Liu","year":"2018","unstructured":"Liu, F. et al. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood 132, 901\u2013901 (2018).","journal-title":"Blood"},{"key":"2269_CR617","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/leu.2017.147","volume":"31","author":"L Chen","year":"2017","unstructured":"Chen, L. et al. Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Leukemia 31, 1830\u20131834 (2017).","journal-title":"Leukemia"},{"key":"2269_CR618","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.1200\/JCO.2019.37.15_suppl.7032","volume":"37","author":"CM Karbowski","year":"2019","unstructured":"Karbowski, C. M. et al. Nonclinical safety assessment of AMG 553, an investigational anti-FLT3 CAR-T therapy. J. Clin. Oncol. 37, 7032\u20137032 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2269_CR619","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/toxsci\/kfaa098","volume":"177","author":"C Karbowski","year":"2020","unstructured":"Karbowski, C. et al. Nonclinical safety assessment of AMG 553, an investigational chimeric antigen receptor T-cell therapy for the treatment of acute myeloid leukemia. Toxicol. Sci. 177, 94\u2013107 (2020).","journal-title":"Toxicol. Sci."},{"key":"2269_CR620","doi-asserted-by":"crossref","unstructured":"Cui, Q. et al. Case report: CD38-directed CAR-T cell therapy: a novel immunotherapy targeting CD38-positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase. Front. Immunol. 13, 1012981 (2022).","DOI":"10.3389\/fimmu.2022.1012981"},{"key":"2269_CR621","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jcyt.2018.05.001","volume":"20","author":"JM Murad","year":"2018","unstructured":"Murad, J. M. et al. Manufacturing development and clinical production of NKG2D chimeric antigen receptor\u2013expressing T cells for autologous adoptive cell therapy. Cytotherapy 20, 952\u2013963 (2018).","journal-title":"Cytotherapy"},{"key":"2269_CR622","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1182\/blood-2018-99-117974","volume":"132","author":"MG Carrabba","year":"2018","unstructured":"Carrabba, M. G. et al. Phase I-IIa clinical trial to assess safety and efficacy of MLM-CAR44.1, a CD44v6-directed CAR-T in relapsed\/refractory acute myeloid leukemia (AML) and multiple myeloma (MM). Blood 132, 5790\u20135790 (2018).","journal-title":"Blood"},{"key":"2269_CR623","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.7150\/jca.28952","volume":"10","author":"H Salman","year":"2019","unstructured":"Salman, H. et al. Preclinical targeting of human acute myeloid leukemia using CD4-specific chimeric antigen receptor (CAR) T Cells and NK Cells. J. Cancer 10, 4408\u20134419 (2019).","journal-title":"J. Cancer"},{"key":"2269_CR624","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.1002\/cam4.5916","volume":"12","author":"K Pei","year":"2023","unstructured":"Pei, K. et al. Anti-CLL1-based CAR T-cells with 4-1-BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia. Cancer Med. 12, 9655\u20139661 (2023).","journal-title":"Cancer Med."},{"key":"2269_CR625","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","volume":"36","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Characteristics of anti-CLL1-based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia 36, 2596\u20132604 (2022).","journal-title":"Leukemia"},{"key":"2269_CR626","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1182\/blood-2020-141214","volume":"136","author":"W Hazelton","year":"2020","unstructured":"Hazelton, W., Ghorashian, S. & Pule, M. Nanobody-based tri-specific chimeric antigen receptor to treat acute myeloid leukaemia. Blood 136, 10\u201311 (2020).","journal-title":"Blood"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02269-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02269-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02269-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T19:02:48Z","timestamp":1751569368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02269-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":626,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2269"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02269-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.M. is a cofounder of OneChain Immunotherapeutics, a spin-off company from the Josep Carreras Leukemia Research Institute. The remaining authors report no conflicts of interest in this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}